Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
09/2011 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions September class, title,number 09/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
09/29/2011 > 197 patent applications in 153 patent subcategories. class, title,number

20110237492 - Treatment of diseases and conditions mediated by increased phosphorylation: The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising... Agent:

20110237493 - Dipeptide linked medicinal agents: A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various... Agent: Indiana University Research And Technology Corporation

20110237496 - Antinecrotic activity of alpha 1-antitrypsin: The present invention is related to the use of alpha-1-antitrypsin as an anti-necrotic agent. This invention provides a method for the treatment of tissue necrosis by administration of alpha-1-antitrypsin. This invention further provides methods for prophylactic treatment of tissue necrosis and for inhibition of tissue necrosis in culture by addition... Agent:

20110237495 - Functional metabolomics coupled microfluidic chemotaxis device and identification of novel cell mediators: The invention relates to the use of microfluidic chemotaxis device to identify novel active compounds of the metabolome and methods to characterize their actions on cell motility. The invention also includes the active compounds of the metabolome identified by the methods and devices disclosed herein. The results from these in... Agent: The Brigham And Women's Hospital, Inc. Corporate Sponsored Research And Licensing

20110237494 - Use of peptidic vasopression receptor agonists: The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of inter alia conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilised are represented by the general... Agent:

20110237497 - Compositions of a v-atpase inhibitor in combination with a glucocorticoid receptor ligand and methods of use: A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having... Agent:

20110237498 - Soluble polypeptides for use in treating autoimmune and inflammatory disorders: The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament,... Agent: Novartis Ag

20110237500 - Cecropin-magainin hybrid peptides: The present invention relates to a biocidal fusion peptide of SEQ ID NO: 1 or a sequence with at least 90% identity thereto, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide, and use of the peptide in treatment, in particular for the treatment of bacterial... Agent: The Secretary Of State Of Defence

20110237499 - Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses: Hybrid tripyrrole-octaarginine compounds. Hybrids formed by a tripyrrole group bound to a polyarginine peptide which permit the efficient cellular internalization and promote a greater affinity for the DNA. The method of obtainment and uses thereof.... Agent:

20110237501 - Detection of mutations in a gene associated with resistance to viral infection, oas1: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the... Agent:

20110237502 - Insecticidal polypeptides and methods of use thereof: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described.... Agent:

20110237503 - Novel peptides and methods for their preparation and use: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity... Agent: Eli Lilly And Company

20110237504 - Delivery agents for enhancing mucosal absorption of therapeutic agents: A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include α-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An... Agent:

20110237505 - Compositions and methods for treating obesity and diabetes: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and... Agent: The Administrators Of The Tulane Educational Fund

20110237506 - Protein stabilization formulations: The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.... Agent: Advanced Technologies And Regenerative Medicine, LLC

20110237507 - Methods of protecting against apoptosis using lipopeptides: The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described.... Agent: Cleveland Biolabs, Inc.

20110237508 - Peptide formulations and uses thereof: The present invention relates to the field of preventive and therapeutic medicine, in particular to peptide formulations. Provided is a pH-buffered aqueous formulation comprising oxytocin, vasopressin or an analogue thereof and at least one non-toxic source of divalent metal ions in a concentration of at least 2 mM, and the... Agent: Rijksuniversiteit Groningen

20110237509 - Hgh and methods for preparing hgh: Preparations of recombinant human growth hormone (hGH) are provided having a purity that comprises 2% or less of a peptide other than native human growth hormone (e.g., essentially free of multimeric forms) are disclosed. Active pharmaceutical ingredient (API) preparations of recombinant hGH suitable for commercial production of formulation grade recombinant... Agent: Elona Biotechnologies

20110237510 - Stabilized glucagon solutions: A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so... Agent: Biodel Inc.

20110237511 - Ep4 receptor agonist, compositions and methods thereof: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of... Agent: Merck Frosst Canada

20110237512 - Methods for treating bleeding disorders using sulfated polysaccharides: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of... Agent:

20110237513 - Ltbp2 as a biomarker for renal dysfunction: The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.... Agent: Pronota N.v.

20110237514 - Pharmaceutical composition for treating bone diseases which comprises protein comprising frizzled1, frizzled2 or frizzled7 extracellular cysteine-rich domain: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of... Agent: Kyowa Hakko Kirin Co., Ltd.

20110237515 - Peptide derived from neurotesin receptor 3 and use thereof in the treatment of psychiatric diseases: The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in... Agent: Universite De Nice Sophia Antipolis

20110237516 - Plant-derived elastin binding protein ligands and methods of using the same: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing... Agent:

20110237517 - Iap inhibitors: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.... Agent: Tetralogic Pharmaceuticals Corp.

20110237520 - Anticancer compounds: e

20110237519 - Hematopoietic growth factor inducible neurokinin-1 gene and uses thereof: The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is... Agent: University Of Medicine And Dentistry Of New Jersey

20110237518 - Method for treating or preventing bladder cancer using the depdc1 polypeptide: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore,... Agent: Oncotherapy Science, Inc.

20110237522 - Neutral nanotransporters: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.... Agent:

20110237521 - Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease: Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms... Agent:

20110237523 - Contraceptive peptides derived from the venom of the spider latrodectus mirabilis, nucleotide sequences to transform a microorganism to produce said peptides; methods to obtain the peptides; pharmaceutical compositions containing thereof and use thereof: Furthermore, a method to obtain the contraceptive peptide is disclosed, said method comprising cloning the nucleotide sequence in a microorganism. A pharmaceutical contraceptive composition comprising at least one peptide according to the abovementioned description and one or more pharmaceutically acceptable vehicles is also described. And finally, the use of the... Agent: Laboratorios Andromaco S.a.

20110237524 - Polymer conjugates of aod-like peptides: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.... Agent: Nektar Therapeutics

20110237525 - Method of ameliorating oxidative stress and supplementing the diet: wherein R1 is an aromatic backbone and R2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction... Agent:

20110237528 - Compositions and methods comprising imidazole and triazole derivatives: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set... Agent: Institute For Oneworld Health

20110237526 - Method for the preparation of a crystalline form: The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable by this method, to a pharmaceutical composition and to the use thereof for preparing medicaments.... Agent: Boehringer Ingelheim International Gmbh

20110237527 - Sglt-2 inhibitors, methods of making them, and uses thereof: The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia,... Agent: Albany Molecular Research, Inc.

20110237529 - Adenosine analogs and their use: The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation,... Agent: Microdose Therapeutx, Inc

20110237530 - Anti-xdr-tb drug, anti-mdr-tb drug, and combination anti-tuberculosis drug: A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:... Agent:

20110237531 - Method for producing sophorose lipid: The present invention provides a low-cost, efficient method for producing a glycolipid biosurfactant, in particular, lactonic sophorose lipids. This method is characterized by culturing a microorganism capable of producing the biosurfactant under limited oxygen supply. The present invention enables preferential production of lactonic sophorose lipids and facilitates recovery of the... Agent: Kaneka Corporation

20110237532 - 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal: The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous... Agent: Boehringer Ingelheim Vetmedica Gmbh

20110237533 - Novel polyphenol compound: e

20110237534 - Methods for treating gastrointestinal diseases: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.... Agent: Cempra Pharmaceuticals, Inc.

20110237535 - Use of induced pluripotent cells and other cells for screening compound libraries: The invention provides methods for screening test compounds or toxins for effects on cells. The invention also provides methods for determining frequency, amplitude and kinetic profiles of cells.... Agent: Sru Biosystems, Inc.

20110237643 - Identification of a novel repressor on ifn-lambda promoter and sirna against zeb1 and blimp-1 to increase ifn-lambda gene activity: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor... Agent: Medical Diagnostic Laboratories, L.L.C.

20110237647 - Inhibitory rna for modulating the molecular function of zfat gene: The inhibitory RNA for inhibiting the expression of ZFAT gene according to this invention decreases a rate of cell proliferation of cancer cells, etc., induces apoptosis of cells including cancer cells, or inhibits an immunoresponse by inhibiting the expression of the ZFAT gene. Therefore, the inhibitory RNA of this invention... Agent: Fukuoka University

20110237646 - Modulation of transthyretin expression for the treatment of cns related disorders: Compounds, compositions and methods are provided for modulating the expression of transthyretin in the brain, specifically the choroid plexus. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with... Agent: Isis Pharmaceuticals, Inc.

20110237648 - Rna interference in skin indications: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.... Agent: Rxi Pharmaceuticals Corporation

20110237651 - Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo: Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural antisense transcript to patients.... Agent: Opko Curna, LLC

20110237649 - Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1: Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.... Agent: Opko Curna, LLC

20110237650 - Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf: Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.... Agent: Opko Curna, LLC

20110237644 - Ubiquitin specific proteases responsible for mcl-1 stability and uses thereof: Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.... Agent: Hybrigenics

20110237645 - Use of rnai technology to inhibit asic3: In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844... Agent: University Of Iowa Research Foundation

20110237652 - Detection and destruction of cancer cells using programmed genetic vectors: In its various embodiments, the invention provides, first, a composition comprising a vector for transfecting a cell. The vector comprises a first nucleic acid encoding an antisense agent having thereon an RNA interference target for a transcript of a gene endogenous to the cell. The vector further comprises a second... Agent:

20110237656 - Method of selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease: The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.... Agent: Trustees Of Dartmouth College

20110237654 - Method to inhibit cell growth using oligonucleotides: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or... Agent: Trustees Of Boston University

20110237655 - Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The... Agent:

20110237653 - Rna vector therapy method: The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver a wide variety of cellular ribonucleic acid molecules to specific types of cells in the body. Utilizing probes on the exterior of the transport devices, the transport devices locate... Agent:

20110237657 - Transport-mediating colloidal pharmaceutical compounds: The invention relates to transport mediator-bonded colloids comprising pharmaceutical substances or fluorescence markers, to a method for the production thereof, and to a pharmaceutical preparation comprising said compounds.... Agent: B. Braun Melsungen Ag

20110237536 - Treating or preventing pain using spicamycin derivatives: The present invention relates to the use of spicamycin derivatives for treatment and/or prevention of pain, including neuropathic pain. The invention further relates to pharmaceutical compositions of spicamycin derivatives suitable for treatment or prevention of pain.... Agent:

20110237537 - Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis: Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are... Agent:

20110237538 - Treatment of lysosomal storage disorders and other proteostatic diseases: Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase... Agent: Summit Corporation PLC

20110237539 - Spinning solution and method for manufacturing biomaterial fibers: Disclosed herein are spinning solutions and methods for manufacturing a biomaterial fiber. The spinning solution includes a biologically absorbable material having a haemostatic function, a polysaccharide selected from the group consisting of hyaluronic acid (HA) and gelatin, and a solvent, wherein the polysaccharide and the haemostatic material exist in a... Agent: Taiwan Textile Research Institute

20110237540 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-taxane conjugates are described herein.... Agent:

20110237541 - Transdermally administered aliskiren: Dosage form of aliskiren, comprising a device for transdermal administration of aliskiren and aliskiren (including salts, prodrugs and metabolites thereof), optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve a desired therapeutic effect. Use of a compound comprising aliskiren, optionally encompassing salts,... Agent:

20110237542 - Composition for preventing adhesion: The composition of the present invention for preventing adhesion exhibits a physical barrier function and a new adhesion prevention function whereby thrombus formation, which is the basis of adhesion, is inhibited. Unlike conventional compositions which simply mixpolymeric substances that function as physical barriers, the present invention performs a more effective... Agent: Postech Academy-industry Foundation

20110237543 - Composition for prevention or treatment of eye diseases: The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1β, TNF-α, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated... Agent: Benebiosis Co., Ltd.

20110237544 - Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use: Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient,... Agent:

20110237546 - Method for treating a mammal by administration of a compound having the ability to release co: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached... Agent:

20110237545 - Trihydroxy polyunsaturated eicosanoid derivatives: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for... Agent: University Of Southern California

20110237547 - Pharmaceutical compositions for the treatment of fungal infections: Synergistic combinations of a squalene epoxidase inhibitor and a leucyl-tRNA synthetase inhibitor are provided, which are useful in particular in the treatment of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g. the skin or nail plays... Agent:

20110237548 - Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline: A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total... Agent: U.s. Nutraceuticals, LLC D/b/a Valensa International

20110237550 - 5-azaindole bisphosphonates: Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.... Agent: Isis Innovation Ltd.

20110237549 - Modulators of rna riboswitches: Provided is a computer model generated from a data array, computer readable storage media encoded with the model, and computers comprising the model, wherein the model is derived from atomic structure coordinates of a FMN riboswitch or a lysine riboswitch. Further provided is a pharmacophore having a spatial arrangement of... Agent: Memorial Sloan Kettering Cancer Center

20110237551 - Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions: o

20110237552 - Composite material consisting of a collagen matrix mineralised with silicate and calcium phosphate phases, method for the production and use thereof: The invention relates to novel composite materials based on a collagen matrix mineralised with silicate and calcium phosphate phases, to a method for the production thereof and use thereof as an implant material which can be shaped in a plurality of ways, a biological coating or active substance carrier. The... Agent: Technische Universitaet Dresden

20110237553 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Abbott Laboratories

20110237554 - Combination therapies: inhibitors of gaba transaminase and nkcc1: Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.... Agent: Children's Medical Center Corporation

20110237555 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.... Agent: Action Medicines

20110237556 - (20s)-2-methylene-19-nor-22-dimethyl-1alpha,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1alpha,25-hydroxyvitamin d3: Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent:

20110237557 - Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3: Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent:

20110237558 - Stabilized composition for treating psoriasis: A storage stable ointment of the present invention comprises a vitamin D compound, a corticosteroid, and an N,N-di(C1-C8)alkylamino substituted, (C4-C18)alkyl(C2-C18)carboxylic ester a (C1-C4)-alkyl(C8-C22)carboxylic ester in a petrolatum ointment base, and optionally containing mineral oil and/or tocopherol. Preferably, the vitamin D compound is calcipotriene, the corticosteroid is selected from the group... Agent:

20110237559 - 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11beta-hydroxysteroid dehydrogenase type-1: In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such... Agent: Schering Corporation

20110237560 - Modulating and/or detecting activation induced deaminase and methods of use thereof: A method for stratifying a subject, said method comprising: measuring the AID expression and/or activity in a first sample of the subject, and comparing said expression and/or activity to a reference AID expression and/or activity, wherein an AID expression and/or activity in the first sample of the subject that is... Agent:

20110237561 - Organic compounds: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.... Agent:

20110237562 - Use of a container of an inorganic additive containing plastic material: The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein.... Agent: Udo Mattern

20110237563 - Fast dissolving drug delivery systems: The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive... Agent:

20110237564 - Imidazopyrimidine derivatives: e

20110237565 - Heterocyclic inhibitors of histamine receptors for the treatment of disease: The present invention relates to compounds and methods which may be useful as inhibitors of H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.... Agent: Kalypsys, Inc.

20110237566 - Therapeutic macrolide compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use... Agent: Merlion Pharmaceuticals Pte Ltd

20110237567 - Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents: This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful... Agent: Xenon Pharmaceuticals Inc.

20110237568 - Crystalline forms: 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine, compositions thereof, preparations thereof, formulations thereof, prodrugs thereof and pharmaceutical uses thereof.... Agent:

20110237569 - Spiro azepane-oxazolidinones as kv1.3 potassium channel blockers: -

20110237570 - Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors: The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit β-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides... Agent: High Point Pharmaceuticals, LLC

20110237571 - Phthalazine derivatives: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.... Agent:

20110237572 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives: in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and... Agent: Novartis Ag

20110237573 - N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators: The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.... Agent: Irm LLC

20110237575 - Inhibitors of fatty acid binding protein (fabp): The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance... Agent:

20110237574 - Use of modified pyrimidine compounds to promote stem cell migration and proliferation: This invention provides cells and methods for stimulating proliferation and migration of endogenous and exogenous mammalian stem cells in vivo and in vitro. The invention provides reagents and methods for efficiently proliferating mammalian stem cells in an animal in need thereof and producing stem cells that can be re-introduced into... Agent:

20110237576 - 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having bace1-inhibiting activity: wherein A is optionally substituted carbocyclic diyl or optionally substituted heterocyclic diyl; B is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R1 is a group such as optionally substituted lower alkyl; R2 is a group such as hydrogen; and R3a and R3b are each independently a... Agent: Shionogi & Co., Ltd.

20110237577 - Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases: The present invention refers to 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) their preparation, use and pharmaceutical compositions useful in the treatment of pathologies associated with microbial pathogens expressing aspartyl-protease activity.... Agent:

20110237578 - Amide compounds, compositions and uses thereof: Compounds are provided according to formula (I), where A, B, W, X′, L, R1, R3, R4b, and m′ are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example,... Agent:

20110237579 - Inhibitors of hcv ns5a: The invention relates to non-macrocyclic, non-peptidic, substituted heterocyclic compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non-structural 5A (“NS5A”) protein of HCV... Agent: Presidio Pharmaceuticals, Inc.

20110237580 - Substituted bicyclic imidazole derivatives as gamma secretase modulators: wherein R0, R1, R3, R4, X, A1, A2, A3, A4, Y1, Y2 and Y3 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said novel... Agent:

20110237581 - Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to... Agent:

20110237582 - Pyrido[3,4-b]indoles and methods of use: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder,... Agent:

20110237583 - 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer: The present invention relates to pyridopyrimidine derivatives according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110237584 - Kynurenine production inhibitor: e

20110237586 - Biaryl compositions and methods for modulating a kinase cascade:

20110237585 - Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase:

20110237587 - 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same: Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.... Agent: Korea Research Institute Of Chemical Technology

20110237588 - Thienylpyri(mi)dinylazole: in which R1 to R8 and X1 have the meanings given in the description, and agrochemically active salts, to their use and to methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on seed of plants and for reducing mycotoxins in plants and parts... Agent: Bayer Cropscience Ag

20110237589 - Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors: corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of... Agent:

20110237590 - Pyridine-3-carboxyamide derivative: r

20110237591 - Plant protection formulations comprising dimethomorph and dithiocarbamate: where the plant protection formulation is formulated as an oil suspension concentrate of the active substances A and B in a liquid organic diluent C which is selected among hydrocarbons, vegetable oils, fatty acid esters and their mixtures, and where the oil suspension concentrate furthermore comprises at least one surface-active... Agent: Basf Se

20110237592 - Substituted amido phenoxybenzamides: in which A, R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the claims, to pharmaceutical compositions and combinations containing said compounds, to methods of preparing said compounds, and to the use of said compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as... Agent: Bayer Schering Pharma Aktiengesellschaft

20110237593 - Topical anti-pruritic compositions and methods of action of same: Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective... Agent: Stiefel Laboratories, Inc.

20110237594 - Fungicide heretocyclyl-triazinyl-amino derivatives: p

20110237595 - Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors:

20110237596 - Heteroaryl-substituted urea modulators of fatty acid amide hydrolase: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating... Agent:

20110237597 - Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity: Methods for treatment of peripheral nerve sensory loss are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.... Agent:

20110237598 - New compounds: t

20110237599 - Heterocyclic inhibitors of histamine receptors for the treatment of disease: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.... Agent: Kalypsys, Inc.

20110237600 - Compounds for improving learning and memory: The present invention provides a compound of Formula I: (I) and methods for improving memory in a subject by administering a therapeutically effective amount of the compound.... Agent: Amnestix, Inc.

20110237601 - Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone... Agent: Millennium Pharmaceuticals, Inc.

20110237602 - Method for treating schizophrenia and related diseases: The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110237603 - Compositions of azimilide dihydrochloride: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.... Agent: Warner Chilcott Company, LLC

20110237604 - Methods for preventing or treating cardiac arrhythmia: Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.... Agent:

20110237605 - Molecular crystal of (4-(1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidine derivative: A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-ylamino)-2-(4-methoxyphenylsulfonamido)propanoic acid is characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04±0.2°. The molecular crystal can be formulated into pharmaceutical composition for treating or controlling diseases resulting from pathological angiogenesis.... Agent:

20110237606 - 3-deazaneplanocin derivatives: This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins.... Agent: Agency Of Science, Technology And Research

20110237607 - Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators: This invention relates to novel substituted purinyl-pyrazol derivatives (I) and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Neurosearch A/s

20110237608 - Pyridopyrimidinone inhibitors of pi3kalpha: i

20110237610 - Quinazoline derivatives as antiproliferative agents: wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are... Agent: Astrazeneca Ab

20110237609 - Antifolate compositions: The present invention provides pharmaceutical compositions comprising an antifolate compound. The compositions can be prepared such that unit dosages of the composition exhibit excellent API content uniformity, such as by wet granulation or hot melt granulation. The pharmaceutical compositions are useful in the treatment of multiple conditions, including abnormal cell... Agent: Chelsea Therapeutics, Inc.

20110237611 - Chemical permeation enhancers enhance nerve blockade by toxins: Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and... Agent: Children's Medical Center Corporation Massachusett S

20110237612 - Thienylamino pyrimidines for use as fungicides: in which to R1 to R10 and X1 and X2 have the meanings given in the description, and agrochemically active salts thereof, their use and also methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on seed of plants, processes for preparing such compositions... Agent: Bayercropscience Ag

20110237613 - Dha esters and use thereof in treatment and prevention of cardiovascular disease: The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV)... Agent:

20110237615 - Narcotic drug formulations with decreased abuse potential: The present application relates to novel narcotic formulations having a decreased injection abuse potential In a representative embodiment, the formulation comprises methadone hydrochloride (6-dimethylamino-4,4-diphenylheptan-3-one, a synthetic opiod), meglumine, cellulose, lactose, and magnesium stearate The application further illustrates methods for making the contemplated formulations.... Agent: Paladin Labs Inc.

20110237614 - Pegylated opioids with low potential for abuse: The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery... Agent: Nektar Therapeutics

20110237616 - Phehylephrine formulations with improveds stability: A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity.... Agent: Novartis Ag

20110237617 - Thieno[2,3-c] isoquinolines for use as inhibitors of parp: p

20110237618 - Methods for treating migraines with huperzine a derivatives: wherein: R represents —NR1R2, —NHC(O)OR3, or —N═CR4R5; R1 represents H, or a C1-6 alkyl; R2 represents H, or a C1-6 alkyl; R3 represents a C1-6 alkyl, a heterocyclic group, or an aryl; R4 represents H, C1-6 alkyl, a heterocyclic group or an aryl; and R5 represents H, C1-6 alkyl, a... Agent:

20110237619 - Imidazopyridine derivatives which inhibit the secretion of gastric acid: The present invention relates to substituted imidazo[1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.... Agent:

20110237620 - Heterocyclic compound and use thereof: (wherein ring A represents an optionally substituted benzene ring; Z represents a group represented by (1) —NR3CO—W1—, (2) —NR3CO—W1—O—, (3) —NR3CO—W1—O—W2—, (4) —NR3CO—W1—S—, (5) —NR3CO—W1—NR4—, (6) —NR3COO—, (7) —NR3COO—W1—, (8) —NR3CO—CO—, or (9) —NR3CONR4— (wherein R3 and R4 each represents a hydrogen atom, etc., and W1 and W2 each represents... Agent: Takeda Pharmaceutical Company Limited

20110237621 - Macrocyclic inhibitors of hepatitis c virus: h

20110237622 - Renin inhibitors: The present invention relates to 3,4-substituted piperidinyl—based renin inhibitor compounds bearing at 4-position oxopyridine or Isoquinolone and having the formula (I): wherein S is Formula (IIa) or Formula (IIb). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal... Agent: Merck Frosst Canada Ltd.

20110237623 - Sustained-release donepezil formulation: A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.... Agent:

20110237624 - Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents: s

20110237625 - Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent: Janssen Pharamceutica N.v.

20110237626 - Compositions for hygienic hand disinfection and disinfectant handwashing: The invention relates to a disinfectant composition which includes a) one or more 1- or 2-(C1- to C24-alkyl)glycerol ethers, b) one or more bispyridiniumalkanes and c) one or more amine oxides, and to the use of the composition for hygienic hand disinfection and for disinfectant handwashing.... Agent: Air Liquide Sante (international)

20110237627 - Methods of synthesizing anatabine: Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment,... Agent: Rock Creek Pharmaceuticals, Inc.

20110237628 - Cyclopentyl- and cycloheptylpyrazoles: a

20110237629 - Amino acid ester prodrugs and the use thereof: The present application relates to amino acid ester prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitriles, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110237630 - Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof: wherein R1 and R2 are each a hydrogen atom, an alkyl group and the like, R3 is a hydrogen atom, an alkyl group and the like, R4 is a hydrogen atom, an alkyl group and the like, m is an integer of 0 to 3, X is a bond, an... Agent:

20110237631 - Selective glycosidase inhibitors and uses thereof: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac.... Agent: Simon Fraser University

20110237632 - Antifouling combination comprising 4-bromo-2-(4- chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile: The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and the biocidal compound 2-butyl-1,2-benzisothiazol-3(2H)one (butylBIT), or a salt thereof, which provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to compositions comprising a combination of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with... Agent:

20110237633 - Small molecule modulators of hepatocyte growth factor (scatter factor) activity: The present invention provides compounds and pharmaceutically acceptable compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which hepatocyte growth factor/scatter factor (HGF/SF) or the activities thereof, or agonists or antagonists thereof, have a therapeutically useful role.... Agent:

20110237634 - Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1: Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions... Agent: Merck Sharp & Dohme Corp.

20110237635 - Tetrahydronaphthalene derivatives: v

20110237636 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV... Agent: Bristol-myers Squibb Company

20110237638 - Metronidazole-based dermatological foam and emulsions for the preparation thereof: i

20110237637 - Metronidazole-based dermatological foam and emulsions for the production thereof:

20110237639 - Imidazolinylmethyl aryl sulfonamide:

20110237640 - Pyrazole phenyl derivatives: and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are... Agent:

20110237641 - Substituted pyrazoles, compositions containing these, method of production and use: d

20110237642 - Process for forming amorphous atorvastatin: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solutilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying... Agent: Pfizer Inc.

20110237658 - Compound and method for the treatment of pain: The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of... Agent: Krishani Biosciences (p) Ltd

20110237659 - Chromenone derivatives as trpv3 antagonists: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and... Agent: Glenmark Pharmaceuticals S.a.

20110237660 - Oral composition: A composition which is adapted for oral consumption comprising daidzein and an anthocyanidin, wherein the weight ratio of daidzein to anthocyanidin is in the range of from 1:1 to 1:100, wherein the daidzein is in the form of a pre-prepared aqueous dispersion, and wherein the composition is free of soy... Agent:

20110237661 - Supplement composition and method of use: The present invention relates to a dietary supplement composition made of: linolinic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or... Agent:

20110237662 - Use of statins to inhibit inflammation and vascular disease: The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of... Agent: Musc Foundation For Research Development

20110237663 - Method for treating philadelphia-negative myeloproliferative syndromes: A method for treating Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea to a patient in need of such a treatment, is described. The diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride in combination with N-hydroxyurea induces... Agent: Italfarmaco Spa

20110237665 - Agrochemical composition comprising pesticide and uv absorber: The present invention relates to an agrochemical composition comprising pesticide and UV absorber, and the abovementioned UV absorbers. The invention furthermore relates to the use of the UV absorbers in agrochemical compositions. It moreover relates to a method of controlling phytopathogenic fungi and/or undesirable plant growth and/or undesirable insect or... Agent: Basf Se

20110237664 - Selective androgen receptor modulators for treating diabetes: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer... Agent:

20110237666 - Hydroxybutyrate ester and medical use thereof: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free... Agent: Human Services

20110237668 - Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, and epilepsy: The present invention relates to compositions and methods for treatment of depression, anxiety, schizophrenia, sleep disorder, or epilepsy comprising monocholine salt of succinic acid of a formula (I) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutically acceptable salt is dicholine salt of succinic acid of a formula (II).... Agent:

20110237667 - Compositions containing diethanol amine esterquats: The invention relates to compositions containing one or more compounds of the formula (1), wherein R1CO and R2CO are linear or branched saturated acyl groups independent of each other, having 18 to 24 C atoms, and A− is a counter-ion, and the total amount of C18-23-alkyl COO groups is 40.0... Agent: Clariant Finance (bvi) Limited

20110237669 - Polyunsaturated fatty acids interactions and oxidative stress disorders: This invention relates to the identification and treatment of the effects of products derived from oxidative pathways for polyunsaturated fatty acid (PUFA) metabolism, i.e., oxidative stress in a patient by monitoring the metabolism of DHA or by administering DHA.... Agent:

20110237670 - Improvement of normal cognitive function: The present invention shows that administration of L-lysine enhances cognitive performance in healthy individuals directly and these improvements persist if L-lysine is continuously administrated. However, when administration is interrupted the cognitive performance returns to baseline.... Agent:

20110237671 - Cosmetic composition comprising vitamin u as active ingredient for healing wounds and reducing wrinkles: Disclosed is a method of using a composition comprising vitamin U as an active ingredient to heal skin wound and inhibit collagenase. The method includes the step of applying an effective amount of the composition on human skin. The vitamin U is included at a concentration of 0.00001-30.0% (w/w) by... Agent: Cuskin Co., Ltd.

20110237672 - Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production: The invention deals with the use of cysteine, a cysteine precursor substance or a cysteine derivative or a cysteine-containing substance to increase the oxygen supply to the tissue by increasing the ventilatory activity and/or by increasing the production of the blood-forming hormone erythropoietin (EPO), especially for the treatment of aging-related... Agent: 2458781 Canada Inc.

20110237673 - Novel niddm regimen: The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent.... Agent: Novo Nordisk A/s

20110237674 - Topical nsaid compositions having sensate component: Topical pharmaceutical compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain.... Agent: Novartis Ag

20110237675 - Pharmaceutical formulations: The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media.... Agent: Abbott Laboratories

20110237676 - Spermicidal and microbicidal compositions: Provided herein are new spermicidal compositions that include one or more fluorous surfactants, e.g., non-ionic fluorous surfactants, anionic fluorous surfactants, cationic fluorous surfactants, and combinations thereof. Also provided are methods of preventing fertilization of an ovum, which include a step of contacting at least one spermatozoon with one or more... Agent: Lehigh University

20110237677 - Inhibitors: The invention relates to inhibitors of tissue transglutaminase II activity and their use as a tocolytic agent.... Agent: The University Of Nottingham

20110237678 - N-(1-methyl-2phenylethyl)benzamide derivatives: A compound of general formula (I). A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it.... Agent: Bayer Cropscience Ag

20110237679 - Novel antiviral compounds, compositions, and methods of use: Compounds, salts thereof, and tautomers thereof are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed.... Agent: Cytokine Pharmasciences, Inc.

20110237680 - Crystal forms of o-desmethylvenlafaxine fumarate: Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof.... Agent:

20110237681 - Inhalable epinephrine: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a... Agent: Civitas Therapeutics, Inc.

20110237682 - S1p receptor modulators for treating mutiple sclerosis: e

20110237683 - Pigment compositions with improved sparking effect:

20110237685 - Photolabile fragrance storage substances: Photolabile fragrance storage substances capable of photo-induced release of odorant aldehydes and odorant ketones are described in addition to a process for long-lasting fragrancing of surfaces and a process for producing said fragrance storage substances.... Agent: Henkel Ag & Co. Kgaa

20110237684 - Process for preparing 4-cyclohexyl-2-methyl-2-butanol: o

20110237686 - Formulations and methods of use: The invention relates to the liquid and lyophilized formulations of small particulates, liposomes, and micelles, and methods for making and using the formulations. In particular, at least in some embodiments, the present invention relates to the production and lyophilization of PEGylated nanoparticles, microparticles, micelles, and liposomes for use and administration... Agent: Cerulean Pharma Inc

20110237687 - Adjusting drug loading in polymeric materials: Drug loading of polymeric materials can be adjusted by selection of materials and/or adjusting processing steps in formation of an implantable drug-loaded device.... Agent: Medtronic Xomed, Inc.

20110237688 - Methods and compositions related to acetylocholine receptor conjugates: Disclosed are methods, compositions, and diagnostic kits for detecting acetylcholine receptor (AchR) autoreactive immune cells in a subject. The methods comprise detecting the binding of AChR-conjugate to penpheral blood AChR-specific B cells for diagnosing autoimmune disorders, including Myasthenia gravis (MG), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA). More specifically,... Agent: The Board Of Regents Of The University Of Texas System

  
09/22/2011 > 181 patent applications in 144 patent subcategories. class, title,number

20110230391 - Fc gamma receptor for the treatment of b cell mediated multiple sclerosis: The invention relates to the Fcγ receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fcγ receptor (Fc-gamma receptor) for use... Agent: Suppemol Gmbh

20110230392 - Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc: The invention provides isolated nucleic acids molecules and proteins, designated NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC... Agent: Millennium Pharmaceuticals, Inc.

20110230393 - Antibacterial phage peptides and methods of use thereof: The present invention is directed to isolated and chimeric polypeptides of bacteriophage origin having antibiotic activity and use thereof in the treatment and control of bacterial infections. Specifically, the present invention is directed to the use of a novel antibacterial polypeptide derived from bacteriophage F87s/06 and chimeric constructs thereof, and... Agent: Lusomedicamenta, S.a.

20110230394 - Processes using antibiotic alternatives in bioethanol production: Methods for controlling the growth of bacteria in ethanol fermentation systems with antibiotic alternatives, which can be nonoxidizing biocides, stabilized oxidizers, or any combinations thereof, are described. As an option, a process or composition of the present invention can include one or more polycyclic antibacterial peptides. The methods can provide... Agent: Buckman Laboratories International, Inc.

20110230395 - Antibacterial agent based on fatty acid esters of hydroxy carboxylic acids: An antibacterial composition includes a combination of fatty acid ester of fatty acid and hydroxy carboxylic acid with an antibacterial agent selected from polylysine, chitosan, protamine, their salts and mixtures hereof. The hydroxy carboxylic acid may be present as acid in its free form, in its salt form and/or in... Agent: Purac Biochem B.v.

20110230396 - Anti-infective compounds and uses thereof: A medicament to prevent or cure fungal infections of the skin or body openings in an immunologically compromised person or animal can comprise Cystatin S, Cystatin SA, Cystatin SN, or similar agents.... Agent: Ith Immune Therapy Holdings Ab

20110230397 - Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer: m

20110230398 - Apolipoprotein c-ii or its active fractions for the prevention or treatment of obesity and related metabolic disorders: Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and therefore an activator of LPL can be an effective agent for the prevention or treatment of obesity or related metabolic disorders,... Agent:

20110230399 - Methods for treating obesity related disease: The present invention relates to methods and products for the treatment of obesity. The invention discloses a method of treating obesity related disease in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a composition which causes the continued down regulation of... Agent:

20110230400 - Nutritional composition for wound healing: A nutritional composition for promoting would healing comprises a protein source, a lipid source and a carbohydrate source wherein no more than 1.8% of the total calories of the composition derive from arginine and wherein the protein source includes praline in an amount of at least 3% of the total... Agent: Nestec S.a.

20110230401 - Insulin fusion polypeptides: We disclose insulin fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.... Agent:

20110230402 - Treating diabetes melitus using insulin injections with less than daily injection frequency: The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of the insulin derivative, wherein said insulin derivative exhibits a prolonged profile of action and wherein... Agent: Novo Nordisk A/s

20110230403 - Glycoside derivatives and uses thereof: e

20110230404 - Glycoproteins produced in plants and methods of their use: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein)... Agent: Ohio University

20110230405 - Peptides and supported peptides for treating skin diseases: The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative... Agent:

20110230406 - Affinity peptides toward bmp-2: We have disclosed affinity peptides toward BMP-2. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for BMP-2.... Agent: Advanced Technologies And Regenerative Medicine, LLC

20110230407 - Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma: Methods are provided for treating and preventing demyelinating diseases including multiple sclerosis, and traumatic injury to the central nervous system including brain trauma and spinal cord injury, by administering a compound or pharmaceutical composition of the invention. Useful compounds include hepatocyte growth factor/scatter factor protein, fragments, fusion polypeptides and muteins... Agent:

20110230408 - Human growth hormone aqueous formulation: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.... Agent: Genentech, Inc.

20110230409 - Glp-i agonist and cardiovascular complications: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.... Agent: Novo Nordisk A/s

20110230410 - Low density lipoprotein receptor-mediated sirna delivery: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are... Agent: Alcon Research, Ltd.

20110230411 - Albumin fibers and fabrics and methods of generating and using same: Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue.... Agent: Zvi Nevo

20110230412 - Neuregulin peptides and their use: The present invention provides certain neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders.... Agent: Zensun (shanghai) Science & Technology Limited

20110230413 - Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis: A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer... Agent:

20110230415 - Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms... Agent:

20110230414 - Pyrrolopyrazine kinase inhibitors: e

20110230416 - Peptide derivatives and use thereof as carriers for molecules in the form of conjugates: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise... Agent: Universite De La Mediterranee

20110230417 - Treatment of diseases and conditions mediated by increased phosphorylation: The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising... Agent:

20110230418 - Anticancer agent: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active... Agent: The Research Foundation For Microbial Diseases Of Osaka University

20110230419 - Iap binding compounds: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis... Agent: Nuevolution A/s

20110230420 - Releasable conjugates for nucleic acids delivery systems: The present invention is directed to nucleic acids delivery systems and methods of modulating an expression of a target gene using the same. In particular, the invention relates to nucleic acids conjugates containing an endosomal release-promoting moiety. The nucleic acids conjugates further contain a nuclear localization signal moiety, and/or a... Agent: Enzon Pharmaceuticals, Inc.

20110230421 - Fusion proteins of apoptin-protein transduction domain of carboxyl-terminus of ec-sod: Provided are fusion proteins of apoptin-protein transduction domain of carboxyl-terminus of EC-SOD, their encoding genes, the recombinant vectors containing said encoding genes, transformants containing said recombinant vectors, as well as the uses and preparation methods thereof. Especially provided are fusion proteins which fuse protein transduction domain of carboxyl-terminus of EC-SOD... Agent:

20110230422 - Purging of an ex vivo hematopoietic stem cell culture of cancer cells: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in... Agent:

20110230423 - Therapy and medicament using integrin ligands for treating cancer: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy... Agent:

20110230424 - Ophthalmic solutions, including contact lens care and eye drops comprising carnosine, preferably in combination with dexpanthenol and/or hyaluronic acid: The current invention relates to a contact lens care solution comprising a compound suitable for treating the eye, or the contact lens, use of such compound in such contact lens care solutions, and methods for introducing such compound in the eye of a person wearing contact lenses. With the current... Agent:

20110230425 - Compositions for protection and cellular delivery of interfering rna: Compositions and methods for protecting and administering small RNA to preserve stability are described. The small RNAs may either be in unmodified form or may be chemically modified to enhance stability further.... Agent: Institute For Systems Biology

20110230426 - Template-fixed peptidomimetics: m

20110230427 - Materials and methods for stabilizing nanoparticles in salt solutions: Sequence-specific polymers are proving to be a powerful approach to assembly and manipulation of matter on the nanometer scale. This has been most impressive in the case of DNA, and progress has been made toward templating inorganic nanoparticles using DNA nanostructures. One obstacle to this progress is that inorganic nanomaterials... Agent:

20110230428 - Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof: Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at... Agent:

20110230429 - Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4\"-or 4'-position: r

20110230430 - Saponin extract from saponaria spp. and uses thereof: A saponin extract from Saponaria vaccaria and its use for stimulating apoptosis in cancer cells and treating cancer is described. The saponin extract may be isolated from Saponaria vaccaria seed. The saponin extract may comprise one or more than one triterpene saponin. The triterpene saponin may comprise a bisdesmosidic saponin... Agent: National Research Council Of Canada

20110230431 - Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections: Provided are topical fosfomycin-tobramycin compositions for the treatment and/or prevention of ophthalmic, otological, and dermatologic inflammation and/or bacterial infections and methods of treating ophthalmic, otological and dermatological inflammation and/or bacterial infections.... Agent: Gilead Sciences, Inc.

20110230432 - Compositions and kits for treating influenza: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.... Agent: Adamas Pharmaceuticals, Inc.

20110230542 - Compositions and methods for inhibiting expression of the pcsk9 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent:

20110230546 - Dsrna compositions and methods for treating hpv infection: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of... Agent:

20110230545 - Eml4-alk fusion gene: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion... Agent: Curegene K.k.

20110230544 - Modulation of c-reactive protein expression: Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.... Agent: Isis Pharmaceuticals, Inc.

20110230543 - Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer: The invention provides novel double stranded oligoribonucleotides that inhibit the Nrf2 gene. The invention also provides a pharmaceutical composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The present invention also relates to methods and compositions for treating or preventing the incidence or severity... Agent: Quark Pharmaceuticals, Inc.

20110230548 - Multicistronic vectors and methods for their design: Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein... Agent: Mannkind Corporation

20110230547 - Potential prognostic markers and therapeutic targets for neurological disorders: We recently found that Satb1 is expressed highly by mature neurons in specific regions of the postnatal brain. Satb2, a homolog of Satb1, is expressed at low levels in the postnatal brain. Neurons respond to external stimuli and rapidly and dynamically change their expression. Satb1 has been found to directly... Agent: The Regents Of The University Of California

20110230433 - Compositions and methods for treatment of cancer: Described herein are novel methods and compositions for treatment of cancer by increasing the mutation rate of cancer cells beyond an error threshold, over which the cancer cells are no longer viable. In particular, mutagenic compounds such as nucleoside analogs for treatment of cancer are also described herein.... Agent: University Of Washington

20110230435 - Methods and compositions for treating obesity and related disorders: The invention provides methods for, and compositions effective for, treating obesity, inhibiting weight gain, treating diabetes mellitus, inhibiting atherosclerosis and treating related disorders and conditions comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may... Agent:

20110230434 - Use of s-adenosylmethionine, vitamin e, and vitamin c for the treatment of oxidative liver injury or insulin resistance: The present invention provides antioxidant compositions comprising S-adenosylmethionine (SAMe), vitamin E and vitamin C and uses thereof for the treatment of liver injury and insulin resistance.... Agent: University Of Manitoba

20110230436 - Uracyl cyclopropyl nucleotides: e

20110230437 - Organic compounds: A composition comprising a compound of formula I CH3CH(OH)CC═O)NR1R2 (I) where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and... Agent: Syngenta Limited

20110230438 - Viscoelastic gel for dermatological use: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants... Agent: Anteis Sa

20110230439 - Methods of reducing absorption of trans fatty acids using water-soluble cellulose derivatives: Provided are food products comprising at least 0.5 g of trans fatty acid per serving and at least 1.33 weight percent of one or more water-soluble cellulose derivatives, based on the total weight of the food product, methods of ameliorating the harmful effects of trans fatty acids on a mammal... Agent:

20110230440 - Inhibitors of fatty acid amide hydrolase: The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for... Agent:

20110230442 - Na channels, disease, and related assays and compositions: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of... Agent: Georgetown University

20110230441 - Stable bortezomib formulations: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with... Agent: Innopharma, LLC

20110230443 - Imidazo[1,2-a] pyridinyl bisphosphonates: Novel imidazo[1,2-α]pyridinyl bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.... Agent: Isis Innovation Ltd.

20110230444 - Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor: A pharmaceutical combination comprising an Hsp90 inhibitor and an mTOR inhibitor, and methods of using the combination to treat or prevent proliferative disorders.... Agent: Novartis Ag

20110230445 - Substituted heteroaryls: p

20110230446 - Cathepsin cysteine protease inhibitors: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.... Agent: Merck Canada Inc.

20110230447 - Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient: Disclosed are: a compound which can be produced through a chemical synthesis at low cost, has an excellent osteogenesis-promoting activity, has high affinity for a bone, and can be applied without the need of any special DDS; and a method for promoting osteogenesis by administering the compound and applying the... Agent: Showa University

20110230448 - Treatment and/or prevention of non-viral epithelial damage: There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic... Agent: Epistem Limited

20110230449 - Alkoxylated phosphoric acid triesters with a high degree of alkoxylation: The invention relates to alkoxylated phosphoric acid triesters of formula (I) wherein x, y and z respectively stand for a number between 51 and 200. The alkoxylated phosphoric acid triesters of formula (I) are characterised especially by advantageous thickening properties.... Agent: Clariant Finance (bvi) Limited

20110230450 - Platelet-activating factor (paf) analogs and uses thereof: Disclosed are novel methods and compositions for treating inflammatory diseases and disorders, utilizing structural analogs of platelet activating factor (PAF).... Agent: Vascular Biogenics Lts

20110230451 - Identification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection: A screening method for identifying compounds that alter the fidelity with which the initiation codon in mRNAs is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity. Methods of altering the fidelity of initiation codon selection are also disclosed.... Agent: The Johns Hopkins University

20110230452 - Compounds and methods for the treatment of pain and other diseases: The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors... Agent:

20110230453 - Use of female mammal's urine for determination of fetal gender related characteristics: e

20110230454 - (aza)indole derivative and use thereof for medical purposes: The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities... Agent: Kissei Pharmaceutical Co., Ltd.

20110230455 - Aqueous-based pharmaceutical composition: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the... Agent: Aventis Pharmaceuticals Inc.

20110230456 - Nitridoosmium(vi) complexes for treatment of cancer: The invention relates to nitridoosmium complexes and methods of using these compounds as treatments for cancer.... Agent: Versitech Limited

20110230457 - Substituted isoquinolinones and quinazolinones: e

20110230460 - Thienotriazolodiazepine derivatives active on apo a: The invention relates to new thienotriazolodiazepine derivatives of the formula (1) wherein R1 is CH3, R2 is CH3 or —(CH2)n—R4 or —(CH2)n—O—R4 or —(CH2)n—S—R4 wherein n is 1, 2, 3 or 4 and R4 is CH3, CH2CH3 or CH2CH2OCH3, and R3 is hydrogen or —OCH2O— or —OCH2CH2O— connected to the... Agent: Circomed LLC

20110230461 - 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives: e

20110230463 - 2h-chromene compound and derivative thereof: [Means for Solution] According to the present invention, a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient of an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal... Agent: Astellas Pharma Inc.

20110230462 - Pyrrolopyrazine kinase inhibitors: e

20110230459 - Lactam acetamides as calcium channel blockers:

20110230458 - Phenyl-heteroaryl derivatives and methods of use thereof:

20110230464 - Purine derivatives useful as p13 kinase inhibitors: This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases.... Agent:

20110230465 - Viral polymerase inhibitors: i

20110230466 - Association of a sinus node if current inhibitor and calcium inhibitor and pharmaceutical compositions containing it:

20110230467 - 4,6-diaminonicotinamide compound: [Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating... Agent: Astellas Pharma Inc.

20110230468 - Fused heterocyclic compounds and uses thereof: e

20110230469 - Method to determine the risk for side effects of an ssri treatment in a person: A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI... Agent:

20110230471 - Benzonaphtyridine compounds as inhibitors of autotaxin: Compounds of the formula (I), in which R1, R2, R3, R4, R5, D, Z, X, Y, m and p have the meanings indicated in Claim 1, can and be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110230470 - Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors: Substituted pyrazolo[4,3-c]pyridine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like... Agent: Nerviano Medical Sciences S.r.l.

20110230473 - Methods and compositions for treating status epilepticus and seizures causing status epilepticus: Disclosed herein are methods, kits and compositions for treating, preventing, inhibiting, or reducing a seizure, status epilepticus, neuropathogenesis or a neuropathology caused by overstimulation of the NMDA receptor pathway and/or exposure to an OP compound.... Agent:

20110230472 - Ring-fused azole derivative having pi3k-inhibiting activity: It is an object of the present invention to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of... Agent: Shionogi & Co., Ltd.

20110230474 - Topical antimicrobial compositions and methods of using same: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient,... Agent:

20110230475 - Method for controlling aphid pests on plants: Plant propagation material expressing aphid resistance and application of an insecticide to the plant propagation material.... Agent: Syngenta Crop Protection, LLC

20110230477 - Compounds, pharmaceutical composition and methods for use in treating metabolic disorders: The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.... Agent: Euroscreen S.a.

20110230476 - Pi3 kinase inhibitors and uses thereof: The present invention provides compounds, compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20110230478 - 4-alkyl-substituted diaminopyrimidines: in which R1 to R13 and X1 and X2 have the meanings given in the description, and agrochemically active salts thereof, and also methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on seed of plants, processes for preparing such compositions and treated seed... Agent: Bayer Sciencecrop Ag

20110230480 - 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders:

20110230479 - Neurotrophin mimetics and uses thereof: The present application is related to compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders associated with p75 expression, such as degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such compounds.... Agent:

20110230482 - Compounds modulating c-fms and/or c-kit activity: Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.... Agent: Plexxikon Inc.

20110230481 - Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a method of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modul: A derivative of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition, a method for using the same, a method for modulating or regulating serine/threonine kinases, and a serine/threonine kinases modulating agent. The invention relates to novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents,... Agent: Selvita S.a.

20110230485 - 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel 6-phenyl-phymidin-4-yl-(phenylannine or phenoxy) derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Neurosearch A/s

20110230484 - Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators: This invention relates to novel pyrazolyl-pyrimidine derivatives and their use as potassium channel modulating agents. In another aspect the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Neurosearch A/s

20110230483 - Pyridine and pyrazine derivative for the treatment of cf: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical... Agent: Novartis Ag

20110230486 - Modulators of hec1 activity and methods therefor: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.... Agent:

20110230487 - Arylsulfonamide ccr3 antagonists: Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.... Agent:

20110230488 - Hybrid-ionone and curcumin molecules as anticancer agents: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based... Agent: Trt Pharma Inc.

20110230489 - S-triazine compounds, pharmaceutical compositions and methods of using the same: L1, L2, L3, R1, R2, R3, R4, R5a, R5b, and R5c are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or... Agent:

20110230490 - Heteroaryl-substituted urea modulators of fatty acid amide hydrolase: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating... Agent:

20110230491 - 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors: r

20110230492 - 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors:

20110230493 - 1-oxa-8-azaspiro [4,5] decabe-8-carboxamide compounds as faah inhibitors: wherein Ar1, Ar2, R1, R2, R3 and R4 are as defined herein and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, fibromyalgia, rheumatoid arthritis, inflammatory... Agent: Pfizer Inc.

20110230494 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20110230495 - 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds: where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates... Agent:

20110230496 - Novel process for preparing highly pure levocetirizine and salts thereof: A process for preparing pure levocetirizine and salts thereof, e.g., the levocetirizine dihydrochloride, and a pharmaceutical composition comprising levocetirizine dihydrochloride produced by the process are disclosed.... Agent: Chemagis Ltd.

20110230498 - Biaryl carboxamides: This invention provides compounds of Formula (I) which are PAFR antagonists: Formula (I) and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful... Agent: Merck Sharp & Dohme Corp.

20110230497 - Biologically active amides: The present invention is directed to biologically active amides which are ligands at the NPY Y5 receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject... Agent: H. Lundbeck A/s

20110230499 - Hsp90 inhibitors for therapeutic treatment: The use of a Hsp90 inhibitor for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain,... Agent: Novartis Ag

20110230500 - Inhibitors of phosphoinositide dependent kinase 1 (pdk1): The instant invention provides for compounds that inhibit PDK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting PDK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent:

20110230501 - Pharmaceutical compositions for the treatment of diabetes mellitus: Disclosed herein is a pharmaceutical composition comprising Hydroxychloroquine or its pharmaceutically acceptable salt and at least one antidiabetic compound, useful in the treatment of diabetes mellitus.... Agent: Ipca Laboratories Ltd.

20110230502 - Modulation of chemosensory receptors and ligands associated therewith: The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors... Agent: Senomyx, Inc.

20110230503 - 6, 9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are provided. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting... Agent:

20110230504 - Alleviating disorders with combining agents that increase epoxygenated fatty acids and agents that increase camp: The present invention relates to compositions and methods for promoting and enhancing the analgesic, anesthetic and anticonvulsant properties of epoxygenated fatty acids, in particular, epoxy-eicosatrienoic acids (“EETs”) and inhibitors of soluble epoxide hydrolase (“sEH”) in the presence of elevated levels of cyclic adenosine monophosphate (“cAMP”) by combining or co-administering the... Agent: The Regents Of The University Of California Office Of Technology

20110230505 - Quinazoline inhibitors of bace 1 and methods of using: Dihydroquinazoline compounds, compositions containing them, the use of the compounds and compositions for the treatment of Alzheimer's disease are described.... Agent: Purdue Research Foundation

20110230506 - Predictive marker for egfr inhibitor treatment: The present invention provides a biomarker (RAPGEF5) that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.... Agent:

20110230508 - Novel forms of a fused pyrrolocarbazole compound: Alternative chemical and/or solid state forms of Compound I, processes to reproducibly make them and methods of treating patients using them.... Agent: Cephalon, Inc.

20110230507 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.... Agent: Prosidion Limited

20110230509 - Methods of use for cyclopamine analogs: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:... Agent:

20110230511 - Carboxamide bioisosteres of opiates: e

20110230512 - Pharmaceutical composition: A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid... Agent: Branded Products For The Future

20110230510 - Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the... Agent:

20110230513 - Pharmaceutical compositions for treatment of parkinsons disease: Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range... Agent: Pharma Two B Ltd.

20110230514 - Morphinan compounds: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor... Agent: Concert Pharmaceuticals Inc.

20110230516 - Ccr1 antagonists and methods of use therefor: i

20110230515 - Compounds and methods for treatment and prevention of diseases: A prodrug compound of a rapamycin analog and methods for inhibiting, treating, and preventing mammalian diseases.... Agent:

20110230517 - Calcium receptor modulating agents: The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula (I). Where Cy1 is pyridinonyl, pyridinyl, quinolinyl or 9-ethyl-9H-beta-carbolinyl,... Agent: Amgen Inc.

20110230518 - Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis: The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.... Agent: Merck Serono S.a.

20110230520 - Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases: Nitrate derivatives of cilostazol are described. They have superior properties and clinical advantages compared to cilostazol in the treatment of vascular and metabolic diseases.... Agent:

20110230519 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.... Agent: Vertex Pharmaceuticals Incorporated

20110230521 - Pyrazole compounds as ccr1 antagonists: Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed... Agent: Boehringer Ingelheim International Gmbh

20110230522 - Biocidal compositions comprising thiol group modulating enzyme inhibitors and pyrion compounds: The present invention relates to combinations of a thiol group modulating enzyme inhibitor and a pyrion compound which provide an improved protecting effect against fouling organisms, fungi or bacteria. More particularly, the present invention relates to compositions comprising a combination of a thiol group modulating enzyme inhibitor selected from dichlofluanid,... Agent:

20110230523 - Transcription factor modulating compounds and methods of use thereof: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.... Agent: Paratek Pharmaceuticals, Inc.

20110230524 - Substituted 2-(5-hydroxy-2-methyl-1h-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases: wherein: R1 represents amino group substituent selected from hydrogen, optionally substituted C1-C5 alkyl, acyl or sulfonyl; R2 and R4 independently of each other represent alkyl substituent selected from hydrogen, halogen, optionally substituted C1-C3 alkyl, optionally substituted hydroxyl, optionally substituted amino group, optionally substituted aminomethyl, substituted mercapto group; R3 represents hydrogen,... Agent: Alla Chem, LLC.

20110230525 - Dual-acting antihypertensive agents: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20110230526 - Thiazolyl mglur5 antagonists and methods for their use: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to... Agent: Merck Sharp & Dohme Corp.

20110230527 - Caspase inhibitors and uses thereof: This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.... Agent:

20110230528 - Use of epothilone d in treating tau-associated diseases including alzheimer's disease: Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.... Agent: Bristol-myers Squibb Company

20110230529 - Benzamide glucokinase activators: The present invention relates to N-heteroaryl-benzamides of the formula (I), pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful as glucokinase activators.... Agent: Transtech Pharma, Inc.

20110230530 - Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive... Agent: Astellas Pharma Inc.

20110230531 - Therapeutic compounds: The invention provides compounds of formula (I) wherein A, B, R1, F, G, n, n′ and the dotted line have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.... Agent:

20110230532 - Nitrooxy cycloalkane derivatives: A compound having the structure wherein Y is selected from the group consisting of —C(O)OR2, —C(O)NHR8, —C(CH2)1-2OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.... Agent:

20110230533 - Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use: Embodiments disclosed herein relate to new imidazolidinedione derivatives, methods of making these compounds, and methods of using the same to prevent, treat, or inhibit malaria in a subject.... Agent:

20110230534 - Composition for local anesthesia: An object of the present invention is to provide a composition for local anesthesia to be added to a local anesthetic drug, the composition showing a sustained local anesthetic effect and having high safety. The object is achieved by a composition for local anesthesia including a drug antagonistic to a... Agent:

20110230535 - Imidazolinylmethyl aryl sulfonamide:

20110230537 - Novel pyrazole-4-n-alkoxycarboxamides as microbiocides: Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection LLC

20110230536 - Phenylpyrazole inhibitors of store operated calcium release: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC... Agent: Calcimedica, Inc.

20110230538 - Pharmaceutical for use in the treatment of ureterolithiasis: The present invention provides pharmaceutical compositions useful for relieving pain caused by ureteral calculi, facilitating exclusion of ureteral calculi or the like. That is, the present invention provides a pharmaceutical composition for the treatment of ureteral lithiasis, which comprises as an active ingredient an indoline derivative represented by the following... Agent: Kissei Pharmaceutical Co., Ltd.

20110230539 - Small molecule inhibitors of n-terminus activation of the androgen receptor: Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as... Agent:

20110230540 - Manassatin compounds and methods of making and using the same: Provided are manassantin compounds and methods of using the compounds. Provided are methods of treating a disease, the method comprising administering a compound according to Formula I. Further provided are pharmaceutical compositions comprising compounds according to Formula I. Also provided are methods of inhibiting HIF-1 in a cell, the methods... Agent: Duke University

20110230541 - Process for the preparation of rotigotine: A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial... Agent: Fidia Farmaceutici S.p.a.

20110230549 - Pharmaceutical compositions for the treatment of pain: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.... Agent: Gw Pharma Limited

20110230550 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Cytokinetics, Inc.

20110230551 - Withaferin a analogs and uses thereof: The present invention provides a novel class of withanolides that have been isolated from W. somnifera under aeroponic conditions or produced semi-synthetically from withanolide natural products. The invention also provides pharmaceutical compositions thereof and methods for using the same in proliferative diseases, neurodegenerative diseases, autoimmune, and inflammatory diseases.... Agent:

20110230553 - Crystallized form of dronedarone base: The invention relates to a novel crystallized form of dronedarone base, to its process of preparation and to pharmaceutical compositions containing said novel crystallized form.... Agent: Sanofi-aventis

20110230552 - Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack: Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack.... Agent: Sanofi-aventis

20110230554 - Method of treating viral infections by administration of ethyl mercury or thiol derivative thereof: Disclosed herein are methods of treating viral infections by administration of ethyl mercury or thiol derivative thereof in an amount effective to treat the viral infection.... Agent: Beech Tree Labs, Inc.

20110230555 - Enzyme inhibitors and the use thereof: The present invention provides compounds and methods for the treatment of diseases or disorders such as heart failure, hyperlipidemia, hypercholesterolemia, gonadotropin deficiency, diabetes mellitus, metabolic syndrome, hyperglycemia, insulin resistance, glucose intolerance, obesity, psoriasis, atopic dermatitis, and cancer.... Agent:

20110230556 - Diglycidic ether derivative therapeutics and methods for their use: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.... Agent:

20110230557 - Polyunsaturated fatty acid and diol ester as an anti-acne agent: The present invention relates to compounds of the following formula (I): where n is an integer between 1 and 15, m is 0, 1, 2 or 3, and R is the hydrocarbon chain of a polyunsaturated fatty acid selected from among omega 3 and omega 6, as well as to... Agent: Pierre Fabre Dermo-cosmetique

20110230558 - Use of cationic surfactants for the inactivation of toxins: This invention relates to a use of a composition for the inactivation of toxins containing cationic surfactants such as ethyl-Nα-lauroyl-L-arginate HCI (LAE). It has been found that cationic surfactants such as ethyl-Nα-lauroyl-L-arginate HCI (LAE) and its salts are effective against endotoxins, exotoxins and aflatoxins.... Agent:

20110230559 - Tranexamic acid formulations: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.... Agent: Ferring B.v.

20110230560 - Synergetic composition comprising flavouring substances and organic acids and use thereof: The present invention relates to a composition comprising a synergetic mixture of flavourings or flavouring substances and organic acids. Moreover, the present invention relates to the use of said composition as a preservative for animal foodstuffs and additives intended preferably for monogastric animals.... Agent: Vetagro S.p.a.

20110230561 - Medical adhesive compositions: A medical adhesive composition comprising, based upon the total weight of the composition, from about 50 wt. % to about 99.9 wt. % of one or more α-cyanoacrylate monomers and from about 0.1 wt. % to about 5 wt. % of one or more non-steroidal anti-inflammatory drugs (NSAIDs). Suitable NSAIDs... Agent:

20110230562 - Melanins synthesized chemically or via enzyme catalysis: The present invention provides an enzymatic and a chemical synthesis of melanins and novel melanins.... Agent:

20110230563 - Amidoacetonitrile compounds and pesticidal composition thereof: Novel amidoacetonitrile compounds are disclosed. The compounds have pesticidal properties and are suitable for controlling endoparasites on warm-blooded animals.... Agent: Novartis Ag

20110230564 - Ant4 inhibitor compounds and methods of use thereof: The invention relates to methods for inducing male contraception and to methods of treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for inducing male contraception and for treating cell proliferation related disorders or diseases.... Agent: University Of Florida Research Foundation

20110230565 - Novel compound containing vanillin and ethylvanillin, and preparation and applications thereof: A compound that includes vanillin and ethylvanillin, and a method for making same are described. The compound described can be obtained by the co-crystallisation of vanillin and ethylvanillin. Methods of using the compound in numerous applicable fields, particularly in human and animal food are also described.... Agent: Rhodia Operations

20110230566 - Perfluorocarbon eye cream formulations: Disclosed are perfluorocarbon compositions for cosmetic applications, in particular, for application to the periocular skin, and methods for using the same.... Agent:

20110230568 - Heating of polymers and other materials using radiation for drug delivery and other applications: The present invention generally relates to systems and methods for releasing a releasable species from an article using an external trigger, for example, using infrared or near-infrared radiation. Such systems and methods may be useful, for example in biological applications (e.g., as an implant within a subject), industrial applications, commercial... Agent: Universidad De Zaragoza

20110230567 - Vinyl alcohol co-polymer cryogels, vinyl alcohol co-polymers, and methods and products thereof: A cryogel-forming vinyl alcohol co-polymer is operable to form a cryogel, i.e., a hydrogel formed by crytropic gelation, in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier. In one embodiment,... Agent:

20110230569 - Lipid formulations comprising a thiolated antioxidant: c

20110230570 - Mask pack comprising cosmetic cotton-like material prepared from paper mulberry: The present invention relates to a cosmetic cotton-like material having excellent air permeability that is prepared from the paper mulberry by removing fiber-binding substances such as pectin and lignin from the paper mulberry fiber, a preparation method thereof and a mask pack comprising the cotton-like material.... Agent: Amorepacific Corporation

20110230571 - Diagnostic and therapeutic protocols: The present invention relates to methods for determining co-receptor usage of an HIV in a subject including the steps of: culturing a viral preparation derived from the subject's plasma with one or more cell lines which express surface CD4 and CCR5, surface CD4 and CXCR4, or surface CD4, CCR5 and... Agent: Monash University

  
09/15/2011 > 186 patent applications in 139 patent subcategories. class, title,number

20110224128 - Methods and compositions for treatment of muscular dystrophy: The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.... Agent:

20110224129 - Lipopeptide compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical... Agent:

20110224130 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20110224131 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20110224133 - Highly potent peptides to control cancer and neurodegenerative diseases: This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity... Agent: University Of Southern California

20110224132 - Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases: It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.... Agent: Tecnogen S.p.a

20110224134 - Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.... Agent: Merck Sharp & Dohme Corp.

20110224135 - Use of conkunitzin-s1 for the modulation of glucose-induced insulin secretion: The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID... Agent: Univesitat Zu Lubeck

20110224136 - Inhibitors of diacylglycerol acyltransferase: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired... Agent:

20110224137 - Inhibitors of diacylglycerol acyltransferase: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired... Agent:

20110224138 - Methods for treating pain induced by injuries and diseases of an articular joint: Described herein are methods for using bone morphogenetic proteins (BMPs), such as OP-1 (also known as BMP-7), to treat pain caused by osteoarthritis. The methods involve administering to a patient suffering from pain caused by osteoarthritis a BMP, for example, intraarticularly by injection directly into the joint afflicted with osteoarthritis.... Agent:

20110224139 - Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage: The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.... Agent: Provasculon, Inc.

20110224140 - Human chorionic gonadotropin (hcg) orally or for injection for the treatment of mood disorders and alcoholism: An HCG preparation for oral administration or for injection used either as a simple dilution or coupled to albumin or a cyclodextrin therapeutically effective in the treatment of mood disorders including (but not limited to) neurosis, irritability, depressive states and borderline states. HCG preparation as above described is also effective... Agent:

20110224141 - Methods and related compositions for the treatment of cancer: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory... Agent: Stc.unm

20110224142 - Parathyroid hormone receptor activation and stem and progenitor cell expansion: The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.... Agent: The General Hospital Corporation

20110224143 - Nucleobindin i variant protein compositions and methods of use: The invention relates to Nucleobindin-1 (NUCB1) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCB1 protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and... Agent: The Research Foundation Of State University Of New York

20110224144 - Compositions and methods for diagnosing and treating mental disorders: The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110224146 - Augmented cognitive training: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining... Agent:

20110224145 - Neuromodulators and methods of use: The present disclosure provides neuromodulators, nucleic acid encoding thereof, and compositions thereof for endowing visual processing abilities to neuronal cells. The present disclosure further provides a method of restoring light sensitivity to degenerate retinas.... Agent: The Regents Of The University Of California

20110224147 - Methods and compositions: A method for inducing an analgesic response to inflammatory or neuropathic pain by administration of 1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1 dimethyl)-4-hydroxyphenyl)methyl piperazine, also called CNSB002 or AM-36, either alone or with an opioid and/or a neurokinin (NK) antagonist.... Agent: Relevare Aust. Pyt. Ltd.

20110224148 - Carbohydrate-polyamino acid-drug conjugates: Compositions that include a polymer conjugate and glucosamine operatively associated with the polymer conjugate, wherein the polymer conjugate includes a first drug, are described herein. Also disclosed herein are methods of using such compositions to treat, ameliorate, or diagnose a disease or condition such as cancer.... Agent: Nitto Denko Corporation

20110224149 - Polynucleotides for use in treating and diagnosing cancers: The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM). The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells. The cancer cells may... Agent:

20110224150 - Methods for effecting regression of tumor mass and size in a metastasized tumor: The present invention relates generally to methods of effecting regression of tumor size and mass of a metastasized tumor in a subject by administering an effective amount of a desulphatohirudin variant.... Agent: Canyon Pharmaceuticals, Inc.

20110224151 - Polymeric micelle composition for treatment of resistant cancer and preparation method of the same: Disclosed are a polymer micelle composition for treatment of resistant cancer cells that contains an amphiphilic double block copolymer and taxane and a P-glycoprotein inhibitor of cyclosporin as its active ingredients, and a method of preparing the same. Said polymer micelle composition for treatment of cancer resistant cells is accumulated... Agent: Samyang Corporation

20110224152 - Synthetic arginine substituted peptides and their use: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.... Agent: Pharmasurgics In Sweden Ab

20110224153 - Asthma associated factors as targets for treating atopic allergies including asthma and related disorders: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated... Agent:

20110224154 - Peptide derivative and composition for promoting tear secretion comprising the same: C

20110224155 - Modulation of chemosensory receptors and ligands associated therewith: The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands.... Agent: Senomyx Inc.

20110224156 - Propionic acids, propionic acid esters, and related compounds: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).... Agent:

20110224157 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Incyte Corporation, A Delaware Corporation

20110224158 - Esterified alpha-galactosylceramide: wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or... Agent: Riken

20110224159 - Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents: The instant application is directed to bidesmosidic betulin and betulinic acid saponin derivatives of formula (I), and use thereof as antitumor agents. In particular, said compounds are effective in treating lung carcinomas, colorectal adenocarcinomas, breast adenocarcinomas, and prostate adenocarcinomas. Methods of synthesizing said compounds through selective glycosylation of the C-28... Agent: Universite Du Quebec A Chicoutime

20110224160 - Use of escin for treatment of type iv hypersensitivity reaction: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated... Agent: Marinomed Biotechnologie Gmbh

20110224161 - Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof: The present invention relates to tetracyclic anthraquinone antibiotic derivatives with anticancer activity. The tetracyclic anthraquinone antibiotic derivatives as provided in the present invention have the same or higher activity than that of the known drugs such as doxorubicin, daunorubicin and the like in the cellular level while having better tolerance... Agent: Tianjin Michele Sci-tech Deveolpment Co., Ltd.

20110224162 - Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity of the inflammatory response: The present invention relates to novel synthetic analogues of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same and to the use thereof in the prevention or treatment of a disease associated with the overexpression of... Agent: Universite D'orleans

20110224279 - Anticancer agent: The present invention relates to a nucleic acid molecule and a pharmaceutical or diagnostic composition for the therapeutic and/or prophylactic treatment or diagnosis of cancer and/or metastasis thereof, comprising a nucleic acid molecule, or an amino acid sequence related to Trim71 and/or its mammalian and non mammalian orthologs and/or a... Agent: Rheinische Friedrich-wilhelms Universitat

20110224283 - Antisense modulation of nuclear hormone receptors: Provided are antisense oligonucleotides and other agents that target and modulate nuclear hormone receptors (NHRs) such as the glucocorticoid receptor (GR), compositions that comprise the same, and methods of use thereof.... Agent: Avi Biopharma, Inc.

20110224282 - Irna agents targeting vegf: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.... Agent:

20110224278 - Methods and compositions for treating a subject for central nervous system (cns) injury: Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments... Agent:

20110224277 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Regulus Therapeutics, LLC.

20110224280 - Pharmaceutical composition comprising anti pcsk9 oligomers: The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as HYPERCHOLESTEROLEMIA AND RELATED DISORDERS.... Agent:

20110224284 - Putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2: The present invention relates in general to microRNA profiling in disease. More specifically, the invention provides for methods and compositions of microRNA to inhibit the growth and formation of tumors.... Agent: University Of Southern California

20110224281 - Rna antagonists targeting hsp70-2: The present invention relates to LNA oligomer compounds (oligomers), which target Hsp70 and mRNA in a cell, leading to reduced expression of Hsp70. Reduction of Hsp70 expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases, such as cancer.... Agent:

20110224287 - Augmented cognitive training: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining... Agent:

20110224286 - Micro rna (mirna) and neurofibromatosis type 1: a role in diagnosis and therapy: The present invention shows that levels of certain micro RNAs (mRNAs) are altered in NF1 cell lines and NF1 tumor cell lines as compared to non-NF1 controls. Methods are provided, e.g., to diagnose NF1 and NF1 tumors. Methods are also provided to treat NF1, NF1 related cancer, and cognitive deficits... Agent: Maine Institute For Human Genetics And Health

20110224285 - Oligomeric compounds for the modulation of hif-1a expression: Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible... Agent: Santaris Pharma A/s

20110224163 - Gel composition for external application containing an adenine compound (as amended): An object of the present invention is to provide a composition for external application that is applied to a part of the skin to more effectively elicit the useful effects of an adenine compound such as adenine, adenosine, and a phosphoric ester of adenosine, and that has long-lasting effects and... Agent:

20110224164 - Fluid compositions for improving skin conditions: The present specification discloses fluid compositions comprising a matrix polymer and stabilizing component, methods of making such fluid compositions, and methods of treating skin conditions in an individual using such fluid compositions.... Agent: Allergan Industrie, Sas

20110224165 - Formulations and methods for reducing waist circumference: Methods for reducing abdominal fat and waist circumference in a human subject are disclosed. The method includes a composition containing Lycium plant that, when administered to a human, can reduce that human's waist circumference.... Agent: Freelife International, Inc.

20110224166 - Composition for activating mitochondria (as amended): The present invention relates to a composition for activating mitochondria which contains a chitooligosaccharide as an active constituent. The chitooligosaccharide can increase the activity of mitochondrial enzymes and increase the amount of mitochondrial DNA, and thus it can be suitably used as an active constituent in the composition for activating... Agent: Amorepacific Corporation

20110224167 - Skin-protecting alkalinity-controlling composition and the use thereof: A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of... Agent: Cp Kelco Aps

20110224168 - Fat-binding compositions: A fat-binding composition contains an inclusion complex with a host molecule and a guest molecule. The guest molecule includes one or more amino acids, vitamins, flavorants or related compounds, rutin, betanin, derivatives thereof, and mixtures thereof. The fat-binding composition may be in the form of a tablet or powder, for... Agent:

20110224169 - Hyaluronic acid oligosaccharide fractions and drugs containing the same: A method for promoting expression of a heat shock protein, or for inhibiting cell injury or cell death, or for treating a disease for which cell or tissue protection is desired, or for promoting production of IL-10, or for inhibiting production of IL-8, by administering an effective amount of a... Agent: Seikagaku Corporation

20110224170 - Pyranopyranone derivatives as antimicrobial agents: m

20110224171 - Inhibitors of fatty acid amide hydrolase: The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for... Agent:

20110224172 - Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods: Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these compounds and methods of treatment using these compounds.... Agent: Gruenenthal Gmbh

20110224173 - C2-c5-alkyl-imidazole-bisphosphonates: b

20110224174 - Creatine ester anti-inflammatory compounds and formulations: The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the... Agent:

20110224175 - Formulations of canfosfamide and their preparation: Formulations of canfosfamide and their preparation.... Agent: Telik, Inc.

20110224177 - Combinations comprising antimuscarinic agents and corticosteroids: A combination which comprises (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent:

20110224178 - Composition and method for treating erectile dysfunction: Erectile dysfunction in a male human patient is ameliorated by oral administration to the patient of a phosphodiesterase type 5 (PDE5) inhibitor, such as sildenafil, and a glucocorticoid such as prednisone.... Agent:

20110224176 - Lyophilized cake formulations: Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stability for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension... Agent: Lithera, Inc.

20110224179 - Medicament and method of diagnosis: We disclose a diagnostic test to determine suitable therapeutic intervention of subjects suffering from subclinical Cushing's syndrome [SCS] and also agents that antagonise the action of cortisol or inhibit excess cortisol production in the treatment of conditions such as SCS in the presence of an adrenal incidentaloma.... Agent:

20110224180 - Novel cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method: The present invention relates to novel chemical compounds, in particular cholest-4-en-3-one oxime derivatives and to the use thereof as medicaments, especially as cytoprotective medicaments, in particular neuroprotective, cardioprotective and/or hepatoprotective medicaments.... Agent:

20110224181 - Methods for the treatment of a traumatic central nervous system injury: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of... Agent: Emory University

20110224183 - 16, 17-carbocyclic condensed steroid compounds having slective estrogenic activity: wherein dotted bonds represent optional double bonds; R6 is H, ═CH2, or —CH3, or —CH2—CH3; R7 is H, C1-4-alkyl, C2-5 alkenyl or C2-5-alkynyl, wherein the alkyl, alkenyl or alkynyl group may be substituted with 1 to 3 halogen atoms independently chosen from the group of fluorine or chlorine atoms; R11... Agent: N.v. Organon

20110224182 - Salts of (3-0-(3',3'-dimethylsuccinyl) betulinic acid and solid state forms thereof: The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use of the compounds for the manufacture of medicaments. The present invention also concerns a method of treatment involving administration... Agent: Myriad Pharmaceuticals, Incorporated

20110224184 - Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis: The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions... Agent: Ramot At Tel Aviv University Ltd.

20110224186 - Carbacephem beta-lactam antibiotics: e

20110224187 - Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof: The present invention relates to novel Pyrrolidine, Piperidine and Piperazine Derivatives, pharmaceutical compositions comprising the Pyrrolidine, Piperidine and Piperazine Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a... Agent:

20110224188 - Derivatives of 6,7-dihydro-5h-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides: Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.... Agent: Boehringer Ingelheim International Gmbh

20110224189 - Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and... Agent:

20110224185 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.... Agent:

20110224190 - Piperidin-4-yl azetidine derivatives as jak1 inhibitors: The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.... Agent:

20110224191 - Substituted pyrrolo[2,3-b]-pyridines and -pyrazines: Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met.... Agent: Osi Pharmaceuticals, LLC

20110224192 - 3-arylamino pyridine derivatives: pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such... Agent:

20110224193 - Inhibitors of diacylglycerol acyltransferase: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired... Agent: Merck Sharp & Dohme Corp

20110224194 - Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity: The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3... Agent:

20110224195 - Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes.... Agent: Merck Sharp & Dohme Corp.

20110224196 - Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil,... Agent: Vivus, Inc.

20110224198 - Aryl methyl benzoquinazolinine m1 receptor positive allosteric modulators: The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20110224197 - Pyrimidines and pyridines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases, such as inhibitors of GSK-3. The invention provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Incorporated

20110224199 - Heterocyclic aromatic compounds useful as growth hormone secretagogues: e

20110224200 - Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient: Provided is a novel prophylactic or therapeutic agent for a chorioretinal degenerative disease. The compound of formula (1) or its salt has inhibitory effects on photoreceptor cell death or visual cell death in a mouse model of light damage. Therefore, the compound or its salt is useful as a prophylactic... Agent:

20110224201 - Cgrp receptor antagonists: Compounds of Formula (I), (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, L, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG, W, Y and Z are as described herein) useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in... Agent:

20110224202 - Pde10 inhibitors and related compositions and methods: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome,... Agent: Omeros Corporation

20110224203 - Benzimidazole derivatives and their use as protein kinase inhibitors: m

20110224204 - Di-substituted phenyl compounds: Di-substituted phenyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. The disclosure also relates to... Agent:

20110224205 - Use of curcumin or its analogues in cancer therapy utilizing epidermal growth factor receptor tyrosine kinase inhibitor: Provided is combined use of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and curcumin or its analogue in cancer therapy, which reduces side effects resulting from the EGFR-TKI and reduces doses of the EGFR-TKI needed for the therapy, particular in a patient resistant to the treatment with the... Agent: National Taiwan University

20110224207 - Flavivirus inhibitors and methods for their use: Methods of treating, preventing, and/or ameliorating a Flavivirus infection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor, e.g., a Flavivirus serine protease inhibitor. These methods are useful in treating, preventing, and/or ameliorating Flavivurs infections such as, for example,... Agent: Georgetown University

20110224208 - Novel inhibitors of flavivirus replication: The present invention relates to a series of Isoquinolone derivatives which are suitable to treat infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Hepatitis C virus (HCV). The present invention also relates to Isoquinolone compounds for use as a medicine for the prevention... Agent: Katholieke Universiteit Leuven, K.u. Leuven R&d

20110224206 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted pyrrole compounds of formula I and compositions comprising substituted tri-substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need... Agent: Synta Pharmaceuticals Corp.

20110224209 - 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (dpp-1): The present invention is directed to 4,4-di-substituted piperidine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.... Agent:

20110224210 - Novel bis-amides as anti-malarial agents: The invention relates to novel bis-amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as... Agent:

20110224211 - Anti-viral compounds, compositions, and methods of use: Disclosed are compounds, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses.... Agent:

20110224212 - Kinase inhibitor compounds: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.... Agent: Tyrogenex, Inc.

20110224213 - Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents: The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents.... Agent:

20110224214 - Process for preparing polymorph: Disclosed is a novel process for preparing crystalline Form II of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide.... Agent: Sanofi-aventis U.s. LLC

20110224216 - Methods of treating or preventing acute erythema: A method of treating or preventing acute erythema in a human in need thereof by topical administration of an effective amount of an alpha adrenergic receptor agonist or pharmaceutically acceptable salt thereof is claimed. The preferred alpha adrenergic receptor agonist is brimonidine. A method of preventing secondary inflammation caused by... Agent: Galderma Laboratories Inc.

20110224217 - Methods of treatment using heteroaryl compounds and compositions thereof: wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an... Agent: Signal Pharmaceuticals, LLC

20110224215 - Pre-surgical treatment: The invention relates to a method of reducing post-surgical bleeding and/or bruising in a patient scheduled to be subjected to a surgical procedure and a patient that was subjected to a surgical procedure. The method involves topically applying to the area and the surrounding area of skin of the patient... Agent: Galderma Laboratories, Inc.

20110224218 - Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds: e

20110224219 - Melanocortin receptor agonists: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.... Agent: Lg Life Sciences Ltd.

20110224221 - Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors: Methods for reducing or preventing the effects of ionizing radiation in healthy cells arc provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Radioprotection can be effected in... Agent:

20110224220 - Substituted tricyclic derivatives: t

20110224222 - Cdk inhibitor for the treatment of mesothelioma: The invention provides a low molecular weight ATP-competitive CDK inhibitor for use in the treatment of mesothelioma. The compound can be administered together with one or more cytotoxic or cytostatic agents.... Agent: Nerviano Medical Sciences S.r.l.

20110224224 - Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate: (e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1... Agent:

20110224223 - Mtor modulators and uses thereof: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.... Agent: Intellikine, Inc.

20110224225 - Inhibitors of protein kinases: wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative... Agent:

20110224227 - Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors: Methods for reducing or preventing the effects of cytotoxic compounds in healthy cells are provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Also described is a method... Agent:

20110224226 - Compositions and methods for increasing blood platelet levels in humans: Disclosed in certain embodiments is an oral pharmaceutical dosage form of a pharmaceutically acceptable excipient and an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl} pyridin-2-yl)piperadine-4-carboxylic acid (Formula I) or a pharmaceutically acceptable salt thereof, to increase platelet levels in humans.... Agent: Akarx, Inc.

20110224228 - Antifungal agents: Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates... Agent: Scynexis, Inc.

20110224230 - Bicyclic dihydroimidazolone cgrp receptor antagonists: Compounds of formula (I): wherein variables B, G1, G2, G3, G4, Ea, Eb, Ec, A1, A2, A3, A4, R6 and RPG and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved,... Agent:

20110224229 - Novel crystalline form: Crystalline Forms of 6-[2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid ethylamide are disclosed together with processes for preparing the Forms, pharmaceutical compositions comprising the Forms, and the use of the Forms in therapy.... Agent: Astrazeneca Ab

20110224231 - Novel lactams as beta secretase inhibitors: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment methods of synthesis, and intermediates are also disclosed.... Agent: Pfizer Inc.

20110224233 - Stem cell cultures: The present invention relates compounds for stabilizing cells and methods of their use.... Agent: The Scripps Research Institute

20110224232 - Treatment of pulmonary fungal infection with voriconazole via inhalation: A method of treating fungal infection by pulmonary administration of a solution of voriconazole and cyclodextrin is provided The fungal infection can be a pulmonary infection. The solution can be an inhalable aqueous formulation that can be administered via the mouth or nose. The cyclodextrin can be a water soluble... Agent: Cydex Pharmaceuticals, Inc.

20110224234 - Polymorph b of n--n-methyl-acetamide: The present invention relates to a method of treating anxiety, epilepsy, sleep disorders, and insomnia, for inducing sedation-hypnosis, anesthesia, and muscle relaxation, and for modulating the necessary time to induce sleep and its duration, which comprises administering a therapeutically effective amount of Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide characterized by a powder... Agent:

20110224235 - Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.... Agent: Pharmacyclics, Inc.

20110224236 - Treatment for pulmonary hypertension: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the... Agent: United Therapeutics Corporation

20110224237 - Use of allopurinol for the treatment of palmar plantar erythrodysesthesia: Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of palmar plantar erythrodysesthesia induced by chemotherapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.... Agent: Nobera Pharma, S.l.

20110224238 - 6, 9-disubstituted purine derivatives and their use for treating skin: The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives.... Agent:

20110224239 - Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor: The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune diseases or cell, tissue or organ graft rejection using such a combination.... Agent:

20110224240 - Methods of treating cancer and related diseases: Disclosed are orally bioavailable compounds effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, such as in cancer and related diseases.... Agent: Myrexis, Inc.

20110224241 - Isothiazole and pyrazole derivatives as fungicides: The present invention relates to compounds of Formula (I) wherein R1, R2, R3 or R4 are as defined in claim 1 or a salt or N-oxide thereof and their use in methods for the control and/or prevention of fungal infection, particularly in plants. The compounds claimed are isothiazole and pyrazole... Agent: Syngenta Crop Protection, Inc.

20110224242 - Styrlyquinolines, their process of preparation and their therapeutic uses: The present disclosure concerns new substituted styrylquinolines, the process of their preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV.... Agent: Bioalliance Pharma

20110224243 - Fzd2 molulators in the treatment of alopecia: An in vitro method for screening candidate compounds for the preventive or curative treatment of alopecia is described. The method can include determining the capacity of a compound to modulate the expression or the activity of a Frizzled 2 (FZD2) transmembrane receptor. Also described, is the use of modulators of... Agent: Galderma Research & Development

20110224244 - Adamantyl benzamide derivatives: Embodiments of the present invention provide adamantyl benzamide derivtives and pharmaceutical compositions comprising adamantyl benzamide derivatives. Methods of use of such compounds and compositions to modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in a subject are also provided.... Agent: High Point Pharmaceuticals, LLC

20110224246 - Pharmaceutical compositions comprising ascomycin: The invention relates to pharmaceutical compositions comprising an ascomycin in dissolved form and a pharmaceutically acceptable cellulose derivative for prevention or reduction of crystal growth.... Agent:

20110224245 - Treatment of neurological disorders using huperzine: Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and/or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and... Agent: President And Fellows Of Harvard College

20110224247 - Azaisoquinolinone derivatives as nk3 antagonists: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.... Agent: H. Lundbeck A/s

20110224248 - Azaquinolones that inhibit prolyl hydroxylase: e

20110224250 - Isoquinoline derivative, and pde inhibitor comprising same as active ingredient:

20110224249 - Novel hydrate form: The present invention relates to a novel hydrate form of moxifloxacin monohydrochloride, processes for preparing the form, pharmaceutical compositions comprising the form and uses of the form and compositions.... Agent: Generics [uk] Limited

20110224251 - Therapeutic pyrazolyl thienopyridines: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more... Agent: Graceway Pharmaceuticals, LLC

20110224252 - Novel imidazole derivatives: The present invention relates to novel imidazole derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is halogen, C1-C4alkyl or C1-C4haloalkyl; R2 is an optionally substituted aryl or heteroaryl; R3 is halogen; R4 is hydrogen, halogen, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy or cyano;... Agent: Syngenta Crop Protection, Inc.

20110224254 - Novel inhibitors: Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.... Agent: Probiodrug Ag

20110224253 - Small-molecule inhibitors of the androgen receptor: The present invention provides tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof. The present invention provides a method of using tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof.... Agent: The Regents Of The University Of California

20110224255 - Tripeptidyl peptidase inhibitors: wherein n is an integer 0 or 1; X represents O; S; or —(CR4R5)m— wherein m is an integer 1 or 2; R4 and R5 are each independently from each other hydrogen or C1-4alkyl; R1 is C1-6alkylcarbonyl optionally substituted with hydroxy; C1-6alkyloxycarbonyl; aminoC1-6alkylcarbonyl wherein the C1-6alkyl group is optionally substituted... Agent:

20110224256 - Therapeutic imprinting for the treatment of psychiatric disorders: The invention features methods, kits, and compositions for the treatment of psychiatric disorders using therapeutic imprinting in pre-pubescent subjects.... Agent:

20110224257 - Bis(difluoromethyl)pyrazoles as fungicides: e

20110224258 - Fungicidal heterocyclic compounds:

20110224260 - Catechol-based derivatives for treating or preventing diabetics: The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetes and ischemia, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and... Agent: National Taiwan University

20110224259 - Novel inhibitors: The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.... Agent: Probiodrug Ag

20110224261 - Crystalline form of 4-(5--4-methyl-4h-1,2,4-triazol-3-yl)pyridine: The present invention relates to a novel crystalline form of 4-(5-{(IR)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it.... Agent: Astrazeneca Ab

20110224262 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient... Agent: Arena Pharmaceuticals, Inc.

20110224263 - Cyclic pyridyl-n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals: in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and... Agent: Sanofi-aventis

20110224264 - Medicaments: Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma.... Agent:

20110224265 - Gel containing pirfenidone: The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions... Agent: Cell Therapy And Technology S.a. De C.v.

20110224266 - 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders: where R1 in each occurrence is independently H or a C1-C4 hydrocarbon; R3 is H, and R4 is a moiety capable of crossing the blood brain barrier selected from the group consisting of: an amino acid, a peptide, transferrin, gluconate, lactate, citrate, malate, fumarate, benzoate, salicylate, pyruvate and propionate. The... Agent:

20110224267 - Selective androgen receptor modulators: This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor... Agent: Radius Health,inc.

20110224268 - Compositions and methods of using r(+) pramipexole: Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.... Agent: Knopp Neurosciences Inc

20110224269 - Analgesic compounds, compositions, and uses thereof: The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.... Agent: Galleon Pharmaceuticals, Inc.

20110224270 - Synergistic microbicidal compositions: This invention relates to synergistic combinations of selected microbicides in combination with a second microbicide or formulation ingredient or raw material. The combinations have greater efficacy than would be expected from combinations of the individual components. The combinations include mixtures of (a) 5-Chloro-2-methyl-4-isothiazolin-3-one+2-Methyl-4-isothiazolin-3-one, :(b) Methyl-4-isothiazolin-3-one, or (c) 1,2-Benzisothiazolin-3-one with one... Agent:

20110224271 - process for the preparation of olmesartan medoxomil: The present invention relates to a process for the preparation and purification of trityl olmesartan medoxomil and olmesartan medoxomil.... Agent: Lek Pharmaceuticals D.d.

20110224272 - Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid: The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.... Agent: Theravance, Inc.

20110224273 - Pyrazole derivatives as 11-beta-hsd1 inhibitors: e

20110224274 - New therapeutic agents: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein... Agent:

20110224275 - Inhibitors of matrix metalloproteinases: The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are... Agent: Wayne State University

20110224276 - optical isomer of phenylpropionic acid and its medicinal use: Optical isomers of phenylpropionic acid drugs are a mixture having R-type optical isomer and S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded. A use of the optical isomers includes that the R-type optical isomer is used for manufacturing anti-inflammatory and analgesic... Agent:

20110224288 - Cancer cell targeting using nanoparticles: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled... Agent:

20110224289 - Compounds of the pterocarpanquinone family, method for preparing the same, pharmaceutical composition containing the new compounds of the pterocarpanquinone family, uses and therapeutic method: This invention belongs to the chemical-pharmaceutical field. New compounds of pterocarpanquinone family presented in formula (I) according to this invention are capable to be activated by reduction generating alkylating species intracellularly. It presents selective cytotoxic effects particularly on mammalian human and nonhuman cells that divide constantly and are useful in... Agent: Universidade Federal Do Rio De Janeiro

20110224290 - Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 μM)+QUER (20 μM) (˜average values of plasma concentrations measured... Agent:

20110224291 - Skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases containing orthodihydroxyisoflavone derivatives: Disclosed herein is a skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases, which contains ortho-dihydroxyisoflavone derivatives as an active ingredient. Specifically, the skin external external composition contains the ortho-dihydroxyisoflavone derivatives, 4′,6,7-trihydroxyisoflavone, 3′,4′,7-trihydroxyisoflavone or a mixture thereof, and thus increases the expression of DKK3 protein and FZD1... Agent:

20110224292 - Method and apparatus for determining anticoagulant therapy factors: Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction... Agent:

20110224293 - Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.... Agent: Sanofi-aventis

20110224294 - Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase: and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an... Agent: Naturewise Biotech & Medicals Corporation

20110224295 - Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use: A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.... Agent: Xenoport, Inc.

20110224296 - Photo-stable pest control: An insecticidal composition comprising stabilized pyrethrins or pyrethroids is provided. Such composition includes stabilizing effective amount of N,N-dialkyl fatty acid amide solvents and certain ultraviolet-light absorbers. In such composition, the pyrethrins or pyrethroid can retain their insecticidal activity for an acceptably long period of time. Therefore, an advantage of this... Agent:

20110224297 - Methods of administering prostratin and structural analogs thereof: This invention relates generally to methods for administering prostratin or a structural analog or metabolite thereof to induce latent HIV-1 expression in mammalian cells. In certain embodiments, prostratin or a structural analog or metabolite thereof is administered by infusion. In an exemplary embodiment, the method of administering prostratin or a... Agent:

20110224298 - Diene compounds for use in human epidermal cell repair and pharmaceutical and cosmetic compositions containing them: i

20110224299 - Stabilized wax composition and uses thereof: Compositions comprising high amounts of low melting point waxes are provided in self-supporting solid or semi-solid form. The low melting point waxes are stabilized in the compositions by the presence of small amounts of higher melting wax. The compositions may provide a cooling sensation when applied to the skin.... Agent: Avon Products, Inc.

20110224300 - Use of potassium 2-(a- hydroxypentyl) benzoate in the manufacture of medicaments for preventing and/or treating senile dementia: The present invention discloses the use of potassium 2-(α-hydroxypentyl) benzoate in the manufacture of medicaments for preventing, relieving or treating senile dementia diseases or symptom, and for relieving oxidative stress injury in brain tissue, increasing neural function of choline, protecting neuron and/or raising the content of brain nerve growth factor.... Agent: Institute Of Mataria Medica, Chinese Academy Of Me

20110224302 - Difluorophenyldiacylhydrazide derivatives: Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110224301 - Hmgb1 expression and protective role of semapimod in nec: Methods are described, which include the administration of semapimod or guanylhydrazone containing compounds, salt thereof, or a combination of the compound and a salt thereof for the inhibition, treatment, and/or prevention of any of NEC, a condition associated with the release of HMGB1, a condition associated with the release of... Agent: Cytokine Pharmasciences, Inc.

20110224303 - Use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders: The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.... Agent:

20110224304 - Biphenylacetamide derivative: The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1-6 alkyl, C1-6 alkoxy substituted with fluorine atom, and others; R4 and R5 are independently selected... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110224305 - Phenylcyclobutylamide derivatives and their stereoisomers, the preparation processes and uses thereof: Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The... Agent: Beijing Yingu Century Pharmacy Co. Ltd

20110224306 - Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry: The present invention relates to the use canthaxanthin and/or 25-hydroxy vitamin D3 (25-OH D3) for improving breeder hatchability and fertility and for lowering embryo mortality in poultry. More particularly, the invention relates to the use of Canthaxanthin and/or 25-hydroxy canthaxanthin in the manufacture of a food or veterinary composition for... Agent: DsmIPAssets B.v.

20110224307 - Antimicrobial compositions comprising trimethylene glycol oligomer and methods of using the compositions: Disclosed are antimicrobial compositions, and methods for killing, inhibiting, or preventing the growth of microbes, using trimethylene glycol oligomers or dimers. The trimethylene glycol oligomers and dimers have the formula R(CH2CH2CH2—O—CH2CH2CH2)nR1 where R and R1 are hydroxyl, amine, or ester functionalitiess, and n is 2 or higher. The antimicrobial compositions... Agent: E. I. Du Pont De Nemours And Company

20110224308 - Organosilicone fine particles, method of production thereof and cosmetic materials, resin compositions and paint compositions containing same: Organosilicone fine particles which are capable of responding to the highly advanced requirements of recent years imposed on them for purposes of actual use, including further improvement in optical characteristics such as total light transmittance and haze as well as heat-resistant colorability related to resin compositions, further improvement in usability... Agent:

20110224309 - Whipped composition for the treatment of keratin fibers: A method for treating a keratinous substrate comprising contacting the keratinous substrate with a composition containing at least one emulsifying agent comprising at least two different polysaccharides and at least one nonionic surfactant; at least one gelling agent; optionally, at least one film former, and a cosmetically acceptable carrier; wherein... Agent: L'oreal

20110224310 - Ceramide dispersion and method for producing same: The present invention provides a ceramide dispersion which includes (1) ceramide-containing particles which contain a ceramide, which are dispersed in an aqueous phase as an oil-phase component and which have a volume average particle diameter from 1 nm to 100 nm, (2) a fatty acid component which is at least... Agent: Fujifilm Corporation

20110224311 - Natural product sweetness enhancers: or a stereoisomer thereof, wherein R2 is rhamnose, and R and R1 are each independently selected from the group consisting of hydrogen, glucose, and beta-sophorose, for enhancing the sweet taste of carbohydrate sweeteners, such as sucrose and fructose. The present invention is also directed to consumables comprising a combination of... Agent:

20110224312 - Engineering porous particles of water soluble therapeutics for pressurized metered-dose inhaler formulations: The subject matter disclosed herein relates to methods for engineering porous particles of water soluble therapeutics with enhanced physical stability and aerosol characteristics in hydrofluoroalkane (HFA)-based pressurized metered-dose inhaler (pMDI) formulations.... Agent: Wayne State University

20110224313 - Compositions and methods for classifying lung cancer and prognosing lung cancer survival: The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and... Agent: British Columbia Cancer Agency Branch

  
09/08/2011 > 116 patent applications in 97 patent subcategories. class, title,number

20110218138 - Pharmaceutical composition containing polypeptide fragments of serralysins: The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the... Agent:

20110218139 - Combination therapy and methods for treating bacterial biofilms: A combination therapy for treating a bacterial biofilm comprises a therapeutically effective amount of an antibiotic comprising an aminoglyco side or tetracycline, or a combination of two or more thereof, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.... Agent:

20110218140 - Biodegradable therapeutic nanoparticles containing an antimicrobial agent: Compositions that include antimicrobial agents and biodegradable delivery-vehicles adapted to enter a cell and release the antimicrobial agents in the cell as they biodegrade. Also provided are compositions that include first and second delivery vehicles including first and second antimicrobial agents, wherein the first delivery vehicles are adapted to release... Agent:

20110218141 - Leptin therapy to increase muscle mass and to treat muscle wasting conditions: The present invention provides a method of treating a subject suffering from a muscle wasting disorder comprising the step of administering to the subject an effective dose of leptin, leptin analog or leptin derivative.... Agent:

20110218142 - Inhibitors of dipeptidylpeptidase iv: The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes... Agent: Trustees Of Tufts College

20110218143 - Compositions and methods for tissue repair: The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof.... Agent: University Of Florida Research Foundation

20110218144 - Method of reducing deleterious effects of ischemia-reperfusion: A therapeutic or prophylactic treatment method of ischemia, such as due to myocardial infarction, by administering thrombopoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The thrombopoietin is administered in a concentration such that the subject's... Agent:

20110218145 - Antibodies to modified human igf-1/e peptides: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E... Agent: Novartis Ag

20110218146 - Adiponectin for treating pulmonary disease: The present invention provides an agent for inhibiting alveolar airspace enlargement containing adiponectin or an agent for inhibiting alveolar wall destruction containing adiponectin. The pulmonary disease therapeutic agents of the present invention are highly safe drugs that possess an excellent effect of decreasing the deterioration of the pulmonary function, such... Agent:

20110218147 - Activin-actriia antagonists for inhibiting germ cell maturation: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.... Agent: Acceleron Pharma Inc.

20110218148 - Pharmaceutical composition: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly(amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly(amino acid)... Agent:

20110218149 - Compositions and methods for treatment of kidney disorders: The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of kidney disease, in particular kidney fibrosis, and other associated conditions.... Agent: Vectus Biosystems Pty Limited

20110218150 - Antiangiogenic polypeptides and methods for inhibiting angiogenesis: Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.... Agent: Abbott Laboratories

20110218151 - Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate: Medicaments and therapeutic compositions contain (1) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, (2) undenatured Type II collagen and, optionally, (3) glucosamine sulfate. One source of the fatty acids or derivatives thereof is fish oil. The... Agent:

20110218152 - Compounds for stimulating p-glycoprotein function and uses thereof: The present invention is directed to polypeptides (e.g., fragments) derived from P-glycoprotein and caveolin-1 which are capable of inhibiting the interaction between these two proteins. Inhibition of this interaction leads to increase of efflux of compounds that are transported by P-gp. The invention further includes methods of treating patients having... Agent:

20110218153 - Topical glutathione formulations for menopausal skin: Topical compositions to address menopausal skin conditions comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24... Agent:

20110218154 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: President And Fellows Of Harvard College

20110218155 - Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides: The invention provides a method for identifying a compound which modulates the activity of a BCL-2 family polypeptide, the method comprising: a) contacting said BCL-2 family polypeptide with a compound under conditions suitable for modulation of the activity of said BCL-2 family polypeptide; and b) detecting modulation of the activity... Agent: Dana-farber Cancer Institute, Inc.

20110218156 - Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules: In accordance with the present invention, it has been discovered that the uptake of negatively charged entities into cells can be enhanced by noncovalently associating such charged entities with molecular entities comprising an amphiphilic core with positively charged arms, wherein a plurality of lipophilic (e.g., bile acid) moieties are covalently... Agent:

20110218157 - Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation in viral infection. For example, polypeptides and other compounds can be used to inhibit binding of DF-associated, immune-complexed IgG anti-DF... Agent:

20110218158 - Dna cytosine deaminase inhibitors: Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.... Agent:

20110218159 - Methods of using inhibitors of sodium-glucose cotransporters 1 and 2: Methods of improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as compounds and pharmaceutical compositions useful therein.... Agent:

20110218160 - Arylalkylamine compound and process for preparing the same: t

20110218162 - 15-thia steroid compounds and compositions: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.... Agent:

20110218161 - Cycloastragenol monoglucoside, preparation, pharmaceutical composition and application thereof: This invention provides a method for preparing cycloastragenol monoglucoside CMG (cycloastragenol-6-O-β-D-glucoside), comprising the steps of: a. using astragaloside IV or Astragali extracts prepared by a conventional method as raw materials and adding an appropriate solvent thereinto to form a raw material solution; b. adding hydrolase and allowing for hydrolysis at... Agent: Tianjin Institute Of Pharmaceutical Research

20110218163 - Paeoniflorin preparations and uses thereof for fat reduction: Disclosed are methods and preparations useful for reducing fat at a targeted area(s) on a human. The preparations comprise as an active ingredient an adipolysis enhancing (i.e., fat-melting) amount of an active ingredient, paeoniflorin (PF). The preparations may be provided as an injectable preparation or as a topically applied preparation,... Agent:

20110218164 - Therapeutic, dietary or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds: s

20110218165 - Use of macrolides in pest control:

20110218166 - Mucoadherents compositions and their use: The present invention has as its objective to provide mucoadherent compositions with enhanced properties of bioadhesivity, consistency, stability and vaginal pH regulation. It can also be the carrier of an active principle for the treatment or prophylaxis of disturbances or diseases caused in mucosa, particularly in the vaginal tract, as... Agent: Incrementha Pd&i - Pesquisa, Desenvolvimento E Inovecao De Famacos E Medicamentos Ltda.

20110218167 - Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments: The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pharmaceutical formulation containing these compounds.... Agent:

20110218168 - Substituted polyamines as inhibitors of bacterial efflux pumps: Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.... Agent: Paratek Pharmaceuticals, Inc.

20110218231 - Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.... Agent: Egen, Inc.

20110218230 - Natriuretic peptide related fragment in cardiovascular disease: This disclosure provides an intracellular fragment of natriuretic peptide receptor A (NPRA), referred to herein as soluble natriuretic peptide receptor-related fragment (sNRF). It is shown herein that sNRF causes NP resistance. Based on these observations, methods of treating a cardiovascular disorder by inhibiting the activity of sNRF are disclosed. Assays... Agent: Oregon Health And Science University

20110218229 - Sirt1 modulation of adipogenesis and adipose function: SIRT1 regulates the physiology of cells of the adipocyte lineage. Modulators of SIRT1 activity can be used to ameliorate, treat, or prevent diseases and disorders associated with adipose physiology, e.g., obesity, an obesity-related disease, or a fat-related metabolic disorder.... Agent:

20110218234 - Gene vector for inducing transgene-specific immune tolerance: A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells.... Agent: Fondazione Telethon

20110218232 - Inhibitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders: The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20110218233 - Treatment of scleroderma: The present invention provides a method of treating scleroderma. The method consists in the upregulation of miR-29 by administration of miR-29 or a miR-29 upregulator which elevates circulating and/or intracellular concentrations of miR-29. The invention likewise relates to the use of miR-29 for such a treatment, and the use of... Agent: Universitat Zurich Prorektorat Mnw

20110218169 - Pirfenidone/toll-like receptor (tlr) agonist compounds and methods of treating neutropenia: The invention disclosed herein relates to compositions and methods for treating subjects suffering from or at risk of developing neutropenia. In some embodiments, the methods comprise administering to a subject suffering from or at risk of developing neutropenia, an effective amount of pirfenidone and one or more toll-like receptor (TLR)... Agent: Intermune, Inc.

20110218170 - Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents: wherein R is individually selected from the group consisting of H, aliphatic acyl, aromatic acyl group, fluoro, chloro, bromo, iodo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano, aryl and nitro; pharmaceutically acceptable salts thereof, prodrugs thereof, solvates thereof and mixtures thereof; are used as inhibitors of DNA... Agent: Southern Research Institute

20110218171 - Trehalose compound, method for producing same, and pharmaceutical product containing the compound: A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X′ each represents a phenyl, a naphthyl, R1—CHR1— (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n′ each independently... Agent: Otsuka Chemical Co., Ltd.

20110218172 - Composition for down-regulating pro-inflammatory markers: The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide faction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises use of polysaccharide fraction... Agent:

20110218173 - Inclusion complexes of pinocembrin with cyclodextrin or its derivatives: Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.... Agent:

20110218174 - Novel cyclic benzimidazole derivatives useful as anti-diabetic agents: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and... Agent: Merck Sharp & Dohme Corp.

20110218175 - Antiviral agents: v

20110218176 - Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and... Agent:

20110218177 - Prodrugs of oxazolidinone cetp inhibitors: The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.... Agent:

20110218178 - Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases: e

20110218180 - Esters of capsaicin for treating pain:

20110218179 - Treatment of lupus nephritis using laquinimod: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject... Agent:

20110218181 - Formulations of deoxycholic acid and salts thereof: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about... Agent: Kythera Biopharmaceuticals, Inc.

20110218182 - Chemical compounds 251: The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their... Agent: Astrazeneca Ab

20110218183 - Fused bicyclic mtor inhibitors: e

20110218185 - Azolotriazinone melanin concentrating hormone receptor-1 antagonists:

20110218184 - Quinolone analogs and methods related thereto: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.... Agent: Cylene Pharmaceuticals, Inc.

20110218186 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Adolor Corporation

20110218187 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy... Agent:

20110218188 - Substituted (pyridyl)-azinylamine derivatives as fungicides: The present invention relates to phenyl-pyrimidinyl-amino derivatives of formula (I) wherein Q1 and p, Ra to Rc, L1, Y, L2 and Q2 represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control... Agent:

20110218189 - Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors: The present invention relates to a pyrrolo[2,3-d]pyrimidin-2-yl-amine derivative according to formula (I) wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said pyrrolo[2,3-d]pyrimidine-2-ylamine derivatives and to their... Agent: N.v. Organon

20110218190 - Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction: The application describes treatment of motoneuronal dysfunctions or disorders using AMPA receptor modulators. Examples of a motoneuronal dysfunction or disorder include obstructive sleep apnea, snoring, multiple sclerosis, spinal cord injury, e.g., crush, partial or complete transection, motor neuron diseases, motor weakness due to aging, stroke, tumor, hemorrhage, degenerative or wasting... Agent: The Regents Of The University Of California

20110218191 - Use of meloxicam for the long term-treatment of kidney disorders in cats: The invention is directed to a formulation containing NSAIDs or a pharmacologically acceptable salt thereof of and one or more vehicles for the treatment of kidney diseases in cats. Serum creatinine concentrations increase less over time following treatment with NSAID compared to untreated cats.... Agent: Boehringer Ingelheim Vetmedica Gmbh

20110218192 - Inhibitors of beta-secretase: The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are... Agent: Vitae Pharmaceuticals, Inc.

20110218193 - Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same: The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess... Agent: Je Il Pharmaceutical Co., Ltd.

20110218194 - Heterocyclic aspartyl protease inhibitors: e

20110218195 - Methods and compositions for treating bacterial infections and diseases associated therewith: The invention features methods and compostions for treating bacterial infections.... Agent: Activbiotics Pharma, LLC

20110218196 - Compounds of estrogen-related receptor modulators and the uses thereof: The compounds according to formula (VIII), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modulating estrogen related receptors (ERR), and treating metabolic diseases, such as high blood fat,... Agent:

20110218197 - Substituted aza-bicyclic imidazole derivatives useful as trpm8 receptor modulators: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular... Agent:

20110218198 - Pyrrolopyridinylpyrimidin-2-ylamine derivatives: Compounds of the formula I in which X, R1, R2, R3, R4 and R6 have the meanings indicated in Claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft

20110218199 - Pyridoneamide derivatives, their manufacture and use as pharmaceutical agents: m

20110218200 - Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine: The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment there-with.... Agent:

20110218201 - Novel pyrazolone-derivatives and their use as pde-4 inhibitors: e

20110218202 - Soluble guanylate cyclase activators: Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their... Agent: Merck Sharp & Dohme Corp.

20110218203 - Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate: This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod... Agent:

20110218204 - Pharmaceutically acceptable salts of novel betulinic acid derivatives: The present invention relates to certain novel salts of Betulinic acid derivatives, to process for preparing such compounds, to use the compounds in treating diseases or disorders mediated by HIV infection, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Hetero Research Foundation, Hetero Drugs Limited

20110218205 - Piperazine derivatives: e

20110218206 - Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use: Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.... Agent:

20110218207 - Isotopically enriched arylsulfonamide ccr3 antagonists: Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.... Agent: Axikin Pharmaceuticals, Inc.

20110218208 - 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases: Methods of treating or suppressing oxidative stress disorders including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-heterocyclylaminoalkyl-(p-quinone) derivatives.... Agent: Edison Phamaceuticals, Inc.

20110218209 - Nutrient delievry drug composition: The present invention is a hypoallergenic nutrient delivery drug composition, that includes an active drug, a binder with non-genetically engineered and non-chemically treated starches and food powders, a filler with non-genetically engineered and non-chemically treated vegetable powder and/or extracts and a non-genetically engineered and non-chemically treated fruit powder and/or extract... Agent:

20110218211 - Azaindole inhibitors of iap: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3′, R4, R4′, R5, R6, R6′ and R9 are as described herein.... Agent: Genentech, Inc.

20110218210 - Compounds for treating abnormal cellular proliferation: Provided herein are compounds, compositions and methods for treating disorders mediated by abnormal cellular proliferation and processes for identifying such compounds.... Agent: Taiga Biotechnologies

20110218212 - Predictive markers for egfr inhibitors treatment: The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31.... Agent:

20110218213 - Methods and compositions for treating or preventing symptoms of hormonal variations: The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations. The receptor antagonist binds to at least one... Agent:

20110218214 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other... Agent: Abbott Laboratories

20110218215 - Compositions and methods for treating social anxiety: The disclosure provides a pharmaceutical composition for treating social anxiety, performance anxiety, and social phobia comprising a therapeutic amount for die treatment of a patient of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound. The β-adrenergic receptor antagonist may be the lipophilic β-blocker propranolol HCl, the... Agent:

20110218216 - Extended release pharmaceutical composition of donepezil: The present invention relates to an extended release pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof and a release-controlling agent. Further, it relates to process for preparation of said compositions.... Agent:

20110218218 - Formulations of indanylamines and the use thereof as local anesthetics and as medication for chronic pain: Internal-dermal formulations of RS—, S—, or R-2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine causing intradermal accumulation of said piperidine and intended for the treatment of neuropathic pain are provided, as well as a method of inducing the relief of pain using the compounds.... Agent: Bridge Pharma, Inc.

20110218217 - Piperidylpropionamide derivatives useful for the treatment of cns disorders including depression and panic disorder: This invention relates to novel piperidine-4-propionamide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20110218219 - Substituted sulphonamido phenoxybenzamides: in which A, R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined in the claims, to pharmaceutical compositions and combinations containing said compounds, to methods of preparing said compounds, and to the use of said compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a... Agent: Bayer Schering Pharma Aktiengesellschaft

20110218221 - Novel histone deacetylase inhibitors, process for preparation and uses thereof: The present invention relates to compounds represented by formula (I) or composition comprising at least one of such compounds, which are inhibitors of histone deacetylase. The detailed description of these compounds is disclosed in the Description. These compounds and the composition comprising the same may be useful as medicaments for... Agent: Central South University

20110218220 - Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution: The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including Mycobacterium tuberculosis.... Agent: The John Hopkins University

20110218222 - Neurorestoration with r(+) pramipexole: Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's... Agent: University Of Virginia Patent Foundation

20110218223 - Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.... Agent:

20110218224 - Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof: The invention provides a micronized 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid having improved stability. The invention also provides pharmaceutical compositions comprising the stable micronized compound, processes for preparing the stable micronized compound, and methods of using the stable micronized compound to treat diseases such as hypertension.... Agent:

20110218225 - Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof: The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression,... Agent: The Regents Of The University Of California

20110218226 - Anti-virulence compositions and methods: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.... Agent:

20110218227 - Hydrate crystals: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal... Agent: Ajinomoto Co., Inc

20110218228 - Crystalline sodium atorvastatin: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.... Agent: Arrow International Limited

20110218235 - Compound and composition and their uses thereof: A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery... Agent: Krishani Biosciences (p) Ltd

20110218236 - Compound and composition and their uses thereof: A compound, composition and method of making and using a compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral,... Agent: Krishani Biosciences (p) Ltd

20110218237 - Compound and composition and their uses thereof: A compound, composition and method of making and using a compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral,... Agent: Krishani Biosciences (p) Ltd.

20110218238 - Compounds, compositions, formulations and their uses thereof: A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery... Agent: Krishani Biosciences (p) Ltd

20110218239 - Use of 5,6-dimethylxanthenone-4-acetic acid as an antiviral agent: The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise... Agent: University Of Maryland Baltimore

20110218240 - Novel compound with spiro chiral carbon backbone, preparation method thereof, and pharmaceutical composition containing the same: Provided are a novel compound with a spiro chiral carbon backbone, a stereoisomer thereof, an enantiomer thereof, an in vivo hydrolysable precursor thereof, or a pharmaceutically acceptable salt thereof. The novel compound with the spiro chiral carbon backbone has excellent osteoblast differentiation activity, mast cell inhibitory activity, and fatty acid... Agent: Snu R & Db Foundation

20110218241 - Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts: Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical... Agent: Cacao Bio-technologies, LLC

20110218242 - Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions: Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.... Agent:

20110218243 - Compositions and methods for treating and/or preventing cardiovascular disease: In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same.... Agent: Amarin Pharma, Inc.

20110218244 - Creatine ß-alaninate: a novel salt for increasing athletic performance: Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.... Agent:

20110218245 - Use of compounds to inhibit 5a-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing them: s

20110218246 - Methods of treating non-nociceptive pain states with gastric retentive gabapentin: Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of... Agent: Depomed, Inc

20110218247 - Formulations of low dose diclofenac and beta-cyclodextrin: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in... Agent:

20110218248 - Organic compounds: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.... Agent:

20110218249 - Use of hypericum perforatum extracts in the treatment of neuropathic pain: Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.... Agent: Aboca S.p.a. Societa Agricola

20110218250 - Composition based on glycerol ether/polyol mixtures: The invention relates to compositions which comprise one or more glycerol ethers together with one or more diol/diols and/or polyol/polyols. As a result, as well as good microbicidal effectiveness, whitening is reduced or avoided, drying-out of the skin is prevented, the moisture content is regulated and the skin is regreased... Agent: Air Liquide Sante (international)

20110218251 - Products with water clusters: A product has solid stable water clusters including a plurality of water molecules connected with one another by electrical dipole interaction via internal electric field of ions and having a permanent electric dipole moment with an electrical field surrounding the solid stable water clusters.... Agent:

20110218252 - Liquid chromatographic fraction of enzymatically polymerized flavonoid as an antioxidant: Disclosed is a separated fraction of a reaction product of an enzymatically catalyzed polymerization of a flavonoid. The separated fraction is highly resistant to oxidation and is useful in numerous applications such as an antioxidant in food products and medical applications.... Agent: Usa As Represented By The Secretary Of The Army

20110218253 - Imaging-based identification of a neurological disease or a neurological disorder: System(s) and method(s) are provided to enable imaging-based identification, detection, evaluation, and mapping of white matter microstructure and hemispheric organization of white matter in a central nervous system (CNS) structure afflicted by a neurological disease or disorder. Various embodiments exploit a set of diffusion tensor metrics to define a classification... Agent:

  
09/01/2011 > 160 patent applications in 119 patent subcategories. class, title,number

20110212881 - Aleurone as a prebiotic fiber for improved intestinal health: The present invention is directed to methods of treating, maintaining or improving the feces quality and gastrointestinal tract health of mammals. The present invention is further directed to food products that can be used to treat, maintain or improve the feces quality and gastrointestinal tract health of mammals. In at... Agent: Cargill Incorporated

20110212882 - Uses of kappa opioid synthetic peptide amides: The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated... Agent: Cara Therapeutics, Inc.

20110212883 - Radical scavenger and active oxygen eliminating agent: It is an object to provide a radical scavenger, an active oxygen-scavenging agent and the like, which are highly efficacious clinically and novel, and so as to attain the object, 3,4-dihydroxyphenylalanine derivatives such as N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) or pharmaceutically acceptable salts thereof are contained as an active ingredient.... Agent: Inbiotex Inc.

20110212884 - Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one... Agent: Synergy Pharmaceuticals, Inc.

20110212885 - Ophthalmic and contact lens solutions containing peptides as preservative: A method and a contact lens solution comprising 0.001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: SEQ ID NO.1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution... Agent:

20110212886 - Pharmaceutical compositions comprising casein derived peptides and methods of use thereof: The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare.... Agent: State Of Israel, Ministry Of Agriculture And Rural Development, Agricultural Research Organization

20110212887 - Methods of treating obesity using enterostatin: The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount of enterostatin. The present invention also provides methods of selecting a subject for therapy with enterostatin. Exemplary disorders or conditions associated with enterostatin... Agent: Harkness Pharmaceuticals, Inc.

20110212888 - Diet and methods for improving learning capacity, mood and behavior in mammals: This invention provides a method of improving mood and learning capacity in a mammal by giving the mammal a meal of low protein food, followed by a second meal of high glycemic index carbohydrate. A composition to be given to a mammal to improve mood and learning capacity and to... Agent:

20110212889 - Use of leptin for the treatment of fatty liver diseases and conditions: The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency.... Agent: University Of Michigan

20110212890 - Metastin derivative and use thereof: Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis inhibiting activity, a cancer proliferation inhibiting activity, a gonadotropin secretion promoting activity, a sex hormone secretion promoting activity). A metastin derivative produced by substituting a constituent amino acid in metastin can be improved in stability in... Agent: Takeda Pharmaceutical Company Limited

20110212891 - Azepinone derivatives: The present invention relates to a compound represented by formula (I): wherein R1 represents a hydrogen atom or the like; R2 and R3 represent a hydrogen atom or the like; R4 is a group represented by (II) R5 represents a phenyl group which may be substituted with a halogen or... Agent: Msd K.k.

20110212892 - Agent for treatment of diabetes: The present invention provides a hypoglycemic agent useful for treating diabetes or other similar diseases which has no adverse effects. Furthermore, the present invention provides a hypoglycemic agent comprising a combination of an antidiabetic drug and 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propanoic acid or a pharmaceutically acceptable salt thereof.... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110212893 - Nell-1 enhanced bone mineralization: Provided herein are methods for enhancing bone mineralization for bone repair or regeneration and compositions and grafts therefor. Methods for screening agents that enhance or modulate NELL-1 gene expression or NELL-1 protein production in a cell are also provided.... Agent: The Regents Of The University Of California

20110212894 - Decellularization method for scaffoldless tissue engineered articular cartilage or native cartilage tissue: Methods for fabricating a tissue-engineered construct comprising: providing a tissue-engineered construct, wherein the tissue-engineered construct is derived from a xenogenic source; and decellularizing the tissue-engineered construct.... Agent:

20110212895 - Treatment of cognitive and learning impairment: Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders.... Agent: Instituto Superiore Di Sanita

20110212896 - Peptides for the treatment of oxidative stress related disorders: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.... Agent: Ramot At Tel-aviv University Ltd.

20110212897 - Wnt3a for inhibition of scarring: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment... Agent: Renovo Limited

20110212898 - Chimeric peptides for the regulation of gtpases: Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer.... Agent: Children's Hospital Medical Center

20110212899 - Corneal neuritogenesis promoter containing pacap and its derivative: It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal... Agent:

20110212901 - Hyaluronic acid derivative and pharmaceutical composition thereof:

20110212900 - Method for prophylactic and/or therapeutic treatment of pain associated with hematopoietic cell transplantation: A method for prophylactic and/or therapeutic treatment of a pain associated with hematopoietic cell transplantation, which comprises the step of administrating thrombomodulin to a mammal.... Agent: National University Corporation Kochi University

20110212902 - Metal-binding compounds and uses therefor: The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further... Agent:

20110212903 - Metal-binding compounds and uses therefor: The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further... Agent:

20110212906 - C-linked glucuronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and methods of using the same to inhibit neoplastic cell growth: e

20110212905 - Crystalline form of 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate: A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.... Agent:

20110212904 - Galactosylated pro-drugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug: Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where... Agent: Stewart Italia Srl

20110212907 - Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain: The present invention relates to novel synthetic hexadecasaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.... Agent: Sanofi-aventis

20110212908 - Topical compositions and the use thereof: The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the... Agent: Virbac Sa

20110212910 - Antioxidant: To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.... Agent: Morinage Milk Industry Co., Ltd.

20110212909 - Use of ginsenoside compound k in the preparation of a medicament for the prevention and treatment of atherosclerosis: The invention relates to the fields of Chinese drugs and chemical drugs, specifically, drugs comprising ginsenoside compounds, methods of using ginsenoside compound K shown in Formula 1 for prevention and treatment of atherosclerosis and uses of ginsenoside compound K in the preparation of a medicament for prevention and treatment of... Agent: Kunming Novoginseng Bioengineering Co., Ltd.

20110212911 - Transcription factor inhibitors and related compositions, formulations and methods: The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general... Agent:

20110212912 - Optimised formulation of tobramycin for aerosolization: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused... Agent: Chiesi Farmaceutici S.p.a.

20110213009 - Adfp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the adipose differentiation-related protein (ADFP),... Agent: Galderma Research & Development

20110213013 - Complexes of small-interfering nucleic acids: The present invention relates to complexes of small-interfering nucleic acids (siNA). Compositions of siNA suited for administration to a patient are described. Methods for delivering the compositions are also described.... Agent: Nektar Therapeutics

20110213014 - Compositions and methods for topical delivery of oligonucleotides: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.... Agent: Isis Pharmaceuticals, Inc.

20110213006 - Compositions and methods for treatment of uncontrolled cell growth: Compositions and methods are provided for the treatment of cancer and other diseases of uncontrolled cell growth. Inhibitors of t-RNA and 28s rRNA are provided as are non-functional amino acid residues for charging of t-RNA molecules. Therapeutic application of the above inhibitors is also provided for the treatment of cancer.... Agent: Immunotrex Corporation

20110213010 - Methods and compositions for the treatment of huntington's disease: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.... Agent: The University Of British Columbia

20110213007 - Micrornas and uses thereof: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of... Agent:

20110213011 - Modulation of smad3 expression: Provided are compounds capable of inhibiting SMAD3 and compositions containing same as well as methods using such compounds for treating fibrosis and scarring.... Agent:

20110213015 - Oligonucleotidic sequences able to silence the expression of the cyclin d1-trop2 chimera and uses thereof in medical field: The invention concerns RNA oligonucleotide sequences or sequences that are transcribed into RNA or analogous molecules able to silence the expression of the CYCLIN D1/TROP2 chimeric mRNA and their use in the treatment and the prevention of tumors.... Agent:

20110213008 - Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor: Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression.... Agent: Senju Pharmaceutical Co., Ltd.

20110213012 - Treatment of cancers characterized by chromosomal rearrangement of the nut gene: The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds.... Agent: Dana-farber Cancer Institute

20110213018 - Compositions and methods for regulation of smooth muscle cells and blood pressure: The invention encompasses a composition for regulating smooth muscle cells. In particular, the invention encompasses a vector comprising a smooth muscle promoter operably-linked to a nucleic acid encoding a calcium-activated potassium channel.... Agent: Board Of Trustees Of The University Of Arkansas

20110213019 - Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death: Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a guanine-rich promoter gene... Agent: University Of Louisville Research Foundation, Inc.

20110213016 - E2epf ubiquitin carrier protein-von hippel-lindau interaction and uses thereof: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by... Agent: Korea Research Institute Of Bioscience And Biotechnology

20110213020 - Immunostimulant compositions comprising a nucleobase and a polysaccharide obtainable from fungi, yeast or bacteria: The present invention relates to compositions comprising nucleobases and/or sources of nucleobases and polysaccharides from extracts of fungi, yeasts or bacteria. Preferably, the compositions include Nucleoforce® or Nucleoforce® Dogs and AHCC®. Said compositions are useful in the treatment and prevention of immunosuppression, of the toxicity derived from chemotherapy or radiotherapy... Agent: Bioiberica, S.a.

20110213017 - Targeted delivery of glycine receptors to excitable cells: The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20110212913 - Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation: The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond... Agent: Provexis Natural Products Limited

20110212914 - Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them: Various pentosan polysulfate (PPS) formulations useful for treatment of osteoarthritis, interstitial cystitis, and other conditions of mammals are provided. These formulations showed improved resistance to degradation and discoloration and improved stability at physiological pH, even after sterilization. Capillary electrophoresis analysis of these formulations indicates that various formulations remain stable under... Agent: Nutramax Laboratories, Inc.

20110212915 - Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them: The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.... Agent: Aventis Pharma S.a.

20110212916 - Method and means for improving bowel health: A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a... Agent: Commonwealth Scientific And Industrial Research Organisation

20110212917 - Agent for ameliorating brain hypofunction: Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of... Agent: School Corporation, Azabu Veterinary Medicine Educational Institution

20110212918 - Boron-containing small molecules: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.... Agent: Anacor Pharmaceuticals, Inc.

20110212920 - N-substituted benzene sulfonamides: i

20110212919 - Protein cross-linking inhibitor:

20110212921 - Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof:

20110212922 - Processes for the preparation of phosphatide salts: The present invention discloses processes a process for the preparation of phosphatide-salt complexes, the process including the steps of: using at least one raw material lecithin as a substrate; and enzymatically processing at least one raw material lecithin with phospholipase-D, racemic or enantiomerically-pure serine, and/or amine in an aqueous carboxylate-salt-complex... Agent: Lipogen Ltd.

20110212923 - Phosphate derivatives of substituted benzoxazoles: The present invention relates to phosphate derivatives of estrogen receptor beta agonists, compositions thereof, preparations thereof, and uses thereof. Formula (I).... Agent: Pfizer Inc.

20110212924 - Compositions and methods to treat cardiac diseases: Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased... Agent:

20110212925 - Novel compounds as receptor modulators with therapeutic utility: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20110212927 - Carbonate prodrugs and methods of using the same: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive... Agent: Neurogesx, Inc.

20110212926 - Water-soluble acetaminophen analogs: The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration. Methods of treating a disease or condition responsive to acetaminophen (such as fever and/or pain) using the acetaminophen prodrugs, as well as kits, unit dosages, and combinations with additional pharmaceutical agent(s) are also provided.... Agent: Neurogesx, Inc.

20110212928 - Methods and compositions for improving cognitive function: The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A... Agent: The Johns Hopkins University

20110212929 - Protein kinase inhibitors: e

20110212930 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors:

20110212931 - Antioxidant: Provided is an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and may be used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains a compound selected from a cyclolanostane compound and... Agent: Morinaga Milk Industry Co., Ltd.

20110212933 - Antiseptic compositions for the treatment of infections: The invention provides antiseptic compositions that comprise a wide spectrum antiseptic component (WSAC) and optionally one or more other active ingredients. The WSAC comprises an alcohol, one or more antimicrobial phenol compounds, one or more antimicrobial agents, a solvent and optionally, one or more non-ionic detergents. Additional components such as... Agent:

20110212932 - Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation: A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention... Agent: Laboratorios Salvat, S.a.

20110212935 - Compositions and treatment methods-4: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Harbor Biosciences, Inc.

20110212934 - Pharmaceutical preparations for treatments of diseases and disorders of the breast: Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the... Agent: Femmepharma Holding Company, Inc.

20110212936 - High-valent palladium fluoride complexes and uses thereof: The present invention provides novel high-valent palladium fluoride complexes. The complexes typically include multi-dentate ligands that stabilize the octahedral coordination sphere of the palladium(IV) atom. These complexes are useful in fluorinating organic compounds, in particular aryl-containing compounds. The invention is particularly useful for fluorinating compounds with 19F for PET imaging.... Agent:

20110212937 - Compounds for the reduction of beta-amyloid production: e

20110212938 - Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119: The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.... Agent: Schering Corporation

20110212939 - Heterocyclic gpcr agonists: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.... Agent: Prosidion Limited

20110212941 - Imidazoisoindole neuropeptide s receptor antagonists: The present invention is directed to imidazoisoindole compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds... Agent:

20110212940 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune... Agent: Epix Pharmaceuticals, Inc.

20110212942 - Inhibitors of polo-like kinase: or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and... Agent: Elan Pharmaceuticals, Inc.

20110212943 - Novel bridged cyclic compounds as histone deacetylase inhibitors: Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth... Agent: Orchid Research Laboratories Limited

20110212944 - 2-oxo-1-pyrrolidine derivatives: This invention relates to novel 2-oxo-1-pyrrolidines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act... Agent:

20110212945 - Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors: The present disclosure relates to new azabiphenylaminobenzoic acid derivatives of formula (I); as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH).... Agent: Almirall, S.a.

20110212946 - Quinolone neuropeptide s receptor antagonists: The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds... Agent:

20110212947 - Substituted indole compounds having nos inhibitory activity: The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such... Agent: Neuraxon Inc.

20110212948 - Treatment of neonate foals with meloxicam: A method of administering meloxicam containing compositions to neonate foals of 6 weeks of age or less is provided. The inventors have discovered that foals of 6 weeks of age or less can have meloxicam administered at a dosage of 0.6 mg/kg without any negative or adverse reaction by the... Agent:

20110212949 - Heterocyclic compounds as pesticides: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.... Agent: Bayer Cropscience Ag

20110212952 - 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents... Agent: Japan Tobacco Inc.

20110212950 - 4,4-disubstituted piperidines: The application relates to 4,4-disubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R2, has the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.... Agent: Novartis Ag

20110212951 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent:

20110212953 - Polymorph form ii of tanaproget: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating... Agent: Wyeth LLC

20110212954 - Alpha-lipoic acid derivatives and their use in drug preparation: The present invention concerns an enantiomer R of a compound of Formula (I), wherein X is —NH—R1 or of Formula (V) or (VI), R1 is —(CH2)n—R2, R2 is a linear, branched or cyclic C1C6 aliphatic group, —O—(CH2)n—CH3, —NH—CO—(CH2)n—CH3, a 5- or 6-membered aliphatic or aromatic ring optionally comprising a heteroatom,... Agent:

20110212955 - Rosamine derivatives as agents for the treatment of cancer: The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together... Agent: Cancer Research Initiatives Foundation

20110212957 - Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands... Agent:

20110212956 - Pyrazolopyrimidines for treating cns disorders: e

20110212958 - Fatty acid raloxifene derivatives and their uses: The invention relates to fatty acid raloxifene derivatives; compositions comprising an effective amount of a fatty acid raloxifene derivative; and methods for treating osteoporosis or preventing invasive breast cancer in postmenopausal women comprising the administration of an effective amount of a fatty acid raloxifene derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20110212959 - Cyanoisoquinoline compounds and methods of use thereof: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:... Agent: Fibrogen, Inc.

20110212960 - New compounds for the treatment of cns disorder: The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer... Agent: Boehringer Ingelheim International Gmbh

20110212961 - Pyrazole derivatives as kinase inhibitors: e

20110212962 - P38 map kinase inhibitors: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.... Agent:

20110212963 - Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof: The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, —COORc-CO—Rc or —CO—NRcRd; where Rc represents alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd represents H, alk or cycloalkyl; these products... Agent: Sanofi-aventis

20110212964 - Modulators of pharmacokinetic properties of therapeutics: e

20110212965 - Inhibitors of histone deacetylase:

20110212966 - Antiviral agents:

20110212967 - Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.... Agent: Incyte Corporation

20110212968 - Phenethylamide derivatives and their heterocyclic analogues: The invention relates to novel phenethylamide derivatives and their wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.... Agent:

20110212970 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20110212971 - Diketo fused azolopiperidines and azolopiperazines as anti-hiv agents: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.... Agent: Bristol-myers Squibb Company

20110212969 - Substituted hydroxamic acids and uses thereof: wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or... Agent: Millennium Pharmaceuticals, Inc.

20110212972 - Compositions and methods for treating female sexual dysfunction: This invention relates to methods, pharmaceutical compositions and kits useful in treating female sexual dysfunction and the use of an estrogen agonist/antagonist for the manufacture of a medicament for the treatment of female sexual dysfunction. The compositions are comprised of an estrogen agonist/antagonist as a first active ingredient and a... Agent: Pfizer Inc

20110212973 - Carbamate compound or salt thereof: [Means for Solution] The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that a piperazine-1-carboxylate compound, in which benzimidazol-2-ylcarbonyl, benzofuran-2-ylcarbonyl or the like binds to the 4-position of the piperazine, has an excellent FAAH inhibitory activity and further has... Agent:

20110212974 - Method for identifying compounds useful for treating and/or preventing disease-associated bone loss: The present invention concerns a method for identifying a compound which inhibits the activation of RAC GTPase by DOCK5 protein comprising the steps of (i) coexpressing the DOCK5 and the RAC proteins in a cell, wherein said DOCK5 protein induces the conversion of inactive RAC, which inactive RAC is bound... Agent: Centre National De La Recherche Scientifique (cnrs)

20110212975 - Antiviral compounds and methods of making and using thereof: Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically... Agent: The University Of Hong Kong

20110212976 - Deuterium-enriched risperidone: The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110212977 - P70 s6 kinase inhibitor and mtor inhibitor combination therapy: The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer,... Agent: Eli Lilly And Company

20110212978 - Combination of zd6474 and pemetrexed: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Astrazeneca Ab

20110212980 - Combinations for the treatment of migraine: The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT1 B/1 D receptor agonist and at least one selective, competitive AMPA receptor antagonist being a 1 H-quinazoline-2,4-dione of formula (I) as defined in... Agent: Novartis Ag

20110212979 - Predictive marker for egfr inhibitor treatment: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.... Agent:

20110212982 - Administration of dipeptidyl peptidase inhibitors: Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.... Agent: Takeda Pharmaceutical Company Limited

20110212981 - Method of determining a chemotherapeutic regimen based on ercc1 and ts expression: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the Probable resistance of a patient's tumor to treatment... Agent:

20110212983 - Platelet adp receptor inhibitors: Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Portola Pharmaceuticals, Inc.

20110212984 - Use of (3r)-4--3-(4-chlorophenyl) butanoic acid for treating urinary incontinence: Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence is disclosed.... Agent: Xenoport, Inc.

20110212985 - Naltrexone long acting formulations and methods of use: The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use... Agent: Alkermes, Inc.

20110212986 - Anti-flavivirus therapeutic: The present invention relates to anti-flavivirus compounds, including lycorine and derivatives thereof, and their use in treating a subject infected by a flavivirus. The present invention also relates to the use of the anti-flavivirus compounds for the prophylaxis of flavivirus infection. The present invention further relates to a method of... Agent: Regents Of The University Of Minnesota

20110212987 - Method of reducing cns and gastrointestinal side affects associated with long-term dextromethorphan/low-dose quinidine combination therapy: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. This invention also provides methods of reducing CNS and gastrointestinal side effects associated with a long term, dextromethorphan/low-dose quinidine combination therapy.... Agent: Avanir Pharmaceuticals, Inc.

20110212988 - Tacrolimus preparation for external applications: The present invention provides tacrolimus containing ointment having low dermal irritation and excellent stability. It was found that an ointment comprising triacetin as a solubilizer for tacrolimus may sufficiently solubilize tacrolimus, has low dermal irritation and excellent stability. Preferably, the ointment of the present invention is an o/o type (oil-in-oil... Agent:

20110212989 - Therapeutic methods and compositions involving isoflavones: in which Z is H, R1 is H or RACO wherein Ra is C1-10alkyl or an amino acid, R2 is H, OH or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected... Agent: Novogen Research Pty Ltd

20110212991 - Diagnostic test for susceptibility to b-raf kinase inhibitors: The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting, patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor.... Agent: Roche Molecular Systems, Inc.

20110212992 - Novel p2x7r antagonists and their use: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.... Agent: Affectis Pharmaceuticals Ag

20110212990 - Novel polymorph of moxifloxacin hydrochloride: The present invention relates to novel polymorph of moxifloxacin hydrochloride, processes for its preparation and to pharmaceutical compositions containing it. Thus, for example moxifloxacin hydrochloride is suspended in methanol and water and the pH is adjusted to 1.0-2.0 with concentrated hydrochloric acid at 25° C. and the separated solid is... Agent: Hetero Research Foundation

20110212993 - Medicament for treating glaucoma comprising as an active ingredient cyclodextrin-clathrate compound of cilostazol: The invention relates to an ophthalmic medicament for treating glaucoma which comprises a clathrate compound prepared by dissolving cilostazol or a salt thereof in a cyclodextrin.... Agent:

20110212995 - Compositions and methods for treating spasticity: Disclosed are methods of treating spasticity by administering to a patient in need of such treatment a compound having the following formula:... Agent: Allergan, Inc.

20110212994 - Small molecule choline kinase inhibitors, screening assays, and methods for safe and effective treatment of neoplastic disorders: Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.... Agent:

20110212996 - Method to predict response to pharmacological chaperone treatment of diseases: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a... Agent: Amicus Therapeutics, Inc.

20110212997 - Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel piperidine-4-acetamide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20110212998 - Pyridine derivatives as s1p1/edg1 receptor modulators: The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.... Agent:

20110212999 - Triazole derivatives and their use as nicotinic acetylcholine receptor modulators: This invention relates to novel triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central... Agent: Neurosearch A/s

20110213000 - N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases: i

20110213001 - Pharmaceutical compositions: The object of the present invention is to provide a pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB. The pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB contains DTCM glutarimide of the Formula (I) as an effective ingredient, thereby being able to... Agent: Keio University

20110213002 - Macrocyclic diterpenes for treating conditions associated with protein kinase c: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides... Agent: Peplin Research Pty Ltd.

20110213003 - Substituted hydroxamic acids and uses thereof: wherein X1, X2, X3, R2, R4b, R1, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases... Agent: Millennium Pharmaceuticals, Inc.

20110213004 - Method of using combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor: Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present... Agent: Hanall Biopharma Co., Ltd.

20110213005 - Methods for treating viral infections: The present invention relates to compounds that modulate ribosomal frameshifting and nucleic acid constructs for use in methods for identifying or validation such compounds. In particular, the present invention relates to the use of nucleic acid constructs to identify or validate compounds capable of modulating the efficiency of programmed ribosomal... Agent:

20110213021 - Compositions and methods for treating nos-associated diseases: The disclosures herein provide lipoic acid salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treat NOS-associated diseases such as inflammatory diseases, metabolic... Agent: Indigene Pharmaceuticals, Inc.

20110213022 - Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities: The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.... Agent: Biolink Life Sciences, Inc.

20110213023 - Method for inhibiting production of cytokines of t helper cell type ii and/or inhibiting production of chemokines using brazilin: A method for inhibiting the production of cytokines of T helper cell type II (Th2 cell) and/or inhibiting the production of chemokines in a mammal is provided, wherein the method comprises administrating to the mammal an effective amount of an active component selected from a group consisting of a compound... Agent:

20110213024 - Two types of crystalline of pinocembrin, their preparation and their use for manufacture of pharmaceutical compositions: Two crystalline forms of pinocembrin of formula (I): α and β, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in... Agent: Cspc Zhongqi West Road Shijazhuang

20110213025 - Catheter lock solutions utilizing tocopherol and mid-chain fatty acids: Methods, compositions and kits are disclosed for infusing a hydrophobic catheter lock solution into an indwelling catheter. The combination of a tocopherol compound and at least one saturated mid-chain fatty acid provides a broad spectrum antimicrobial solution with optimal viscosity for effectively locking a catheter. The lock can effectively reduce... Agent: Proviflo, LLC

20110213026 - Extracts with liver-x-receptor modulators, compounds and their use especially in weight control: The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, of an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from the group consisting of... Agent: Intermed Discovery Gmbh

20110213027 - Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.... Agent: Sanofi-aventis

20110213028 - Fatty acid mycophenolate derivatives and their uses: The invention relates to fatty acid mycophenolate derivatives; compositions comprising an effective amount of a fatty acid mycophenolate derivative; and methods for treating and preventing organ rejection and autoimmune diseases such as systemic lupus erythematosus, psoriasis and multiple sclerosis comprising the administration of an effective amount of a fatty acid... Agent: Catabasis Pharmaceuticals, Inc.

20110213029 - 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands: e

20110213030 - External preparation for skin: An external preparation for skin containing an alkylresorcinol and being excellent in temperature stability (especially high-temperature stability) and photostability. More particularly an external preparation for skin comprising (a) from 0.01 to 5% by mass of 4-isobutyl resorcinol or a salt thereof, and (b) from 0.01 to 5% by mass of... Agent: Shiseido Company, Ltd.

20110213031 - Novel type i natural ceramide derivative and method for producing same: The present invention aims to provide a novel type I natural ceramide derivative having a structure more similar to that of a type I natural ceramide composed of sphingosine and an ω-acyloxy long-chain carboxylic acid; and a method for producing the same. The derivative is provided by reacting an ω-acyloxy... Agent: Kaneka Corporation

20110213032 - Fatty acid c16: 1n7-palmitoleate a lipokine and biomarker for metabolic status: The present invention provides for a novel lipokine, C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, a low concentration of C16:1n7-palmitoleate in the free acid component of the serum indicates a risk of metabolic disease, and that de novo lipogenesis should be stimulated. Additionally, administering C16:1n7-palmitoleate... Agent: President And Fellows Of Harvard College

20110213034 - Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same: Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, or a combination thereof, and methods of using the same.... Agent:

20110213033 - Skin conditioner: (wherein, the symbols are the same as those defined in the text). Examples of active ingredients of the present invention include L-arginine and ethanolamine. These active ingredients can be acquired as chemical synthesis products, or they may also be acquired in the form of natural substances. Preferable examples of natural... Agent: Kabushiki Kaisha Soken

20110213035 - Biocide agents against marine woodborers: The present invention relates to biodegradable biocide agents against marine woodborers. In particular, the present invention relates to novel slow releasing biocide impregnating solutions against marine woodborers, and methods of creating anti marine woodborer environments.... Agent: Teredo Marine Protection Aps

20110213036 - Composition for prevention of tooth hypersensitivity: The present invention relates to a composition for prevention of tooth hypersensitivity, and more particularly to a composition for prevention of tooth hypersensitivity, which comprises an adhesive polymer for coating teeth, an active ingredient for prevention of hypersensitivity, a substance for promoting the penetration of the active ingredient for prevention... Agent: Nano Intelligent Biomedical Engineering Corporation Co. Ltd.

20110213037 - Methods for concomitant administration of colchicine and macrolide antibiotics: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.... Agent: Mutual Pharmaceutical Company, Inc.

20110213038 - Control of bed bugs: Control of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one of carvone, linalool, styralyl alcohol, dihydrocarvone, tetrahydrocarvone, and mixtures thereof and method for achieving such control.... Agent:

20110213039 - Infant formulas containing docosahexaenoic acid and lutein: Disclosed is a method of reducing the risk or severity of retinopathy of prematurity in preterm infants. The method comprises (a) measuring skin carotenoid levels in preterm infants, preferably by Raman Spectroscopy, and then (b) administering supplemental carotenoids to those infants in need thereof, wherein the supplemental carotenoids comprise lutein,... Agent: Abbott Laboratories, Inc.

20110213040 - Process for production of fatty acids and wax alternatives from triglycerides: A method of producing volatilized fatty acids by heating a feedstock comprising at least one fat or oil in a reactor under inert vacuum to volatilize fatty acids, and removing volatilized fatty acids from bottoms residue comprising cross-linked oil. A system for stripping fatty acids from triglycerides, the system comprising... Agent: H R D Corporation

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 5.79614 seconds

PATENT INFO